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ABSTRACT 
Marcel Yotebieng 
Optimization of pediatric antiretroviral therapy in sub-Saharan Africa: Timing of initiation 
in HIV/TB co-infected children and using weight, height, and CD4 gain to monitor the 
response   
 (Under the direction of Frieda Behets, PhD, MPH) 
 
Backgroung: Antiretroviral therapy (ART) has revolutionized the treatment of HIV, but 
substantial drug interactions between anti-TB and ART and the lack of health care 
infrastructures complicate the management of HIV/TB co-infected children in resource 
poor countries. More than 50% of TB infected children in some high burden countries in 
sub-Saharan Africa are also infected with HIV, but the optimal timing of ART in those 
children is unknown. In addition, though the drug-interactions and the high pill burden to 
treat HIV and TB require strict monitoring, regular measurements of viral load that is 
routine for ART monitoring in developed countries is not always possible in sub-
Saharan Africa. This study had two aims. 1) Construct reference charts for gains in 
weight, height, absolute CD4 count, and CD4% in the first 6 months of ART, and to test 
the value of the 3rd, 10th, 25th, 33rd, and 50th percentiles as predictors of subsequent 
death, virological suppression, or treatment failure. 2) Determine the effect of delaying 
ART for at least 15, 30, or 60 days in HIV/TB co-infected children on virological 
suppression and survival.  
 
Methods: We used information from an observational clinical cohort of HIV-infected 
children who sought care at an outpatient clinic at Chris Hani Baragwanath Hospital in 
Soweto, South Africa. To construct the reference charts, we assumed a Box Cox 
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power exponential distribution for the 6 month gains in weight, height, CD4 count and 
CD4% and used the generalized additive model for location, scale, and shape to 
estimate the parameters of each of the four distributions. Hazard ratios for the 
association of the selected centiles with the three outcomes were estimated using Cox 
proportional hazard model. For aim 2, though per guidelines all HIV-infected children 
with TB were eligible for ART, the decision whether to initiate or delay ART for a given 
child was made at each visit and sicker children were initiated earlier. Moreover, some 
children for whom ART was delayed could die before it was possible to classify them for 
exposure. To control for the time-dependent confounding by indication and the lead time 
on survival, mortality hazard ratios were estimated using the inverse-probability-of-
treatment-weighting of marginal structural modelling. Adjusted hazard ratios for 
virological suppression were estimated using multivariate Cox proportional modelling.   
Results: Overall, information from 1394 and from 573 children was used for aim 1 and 
aim 2 respectively.  
Children whose weight, absolute CD4, or CD4% gain were below the 33rd percentile for 
age or gender had poorer ART outcomes with a three to four-fold  higher hazard of 
death, about 0.75 -fold lower hazard of virological suppression and about two-fold 
higher hazard of treatment failure.  
Delaying ART tended to be associated with increased mortality: adjusted hazard ratios 
(aHR) for 15, 30, and 60 days delay were: 0.90 (95%CI: 0.30, 2.75), 1.05 (95%CI: 0.29, 
3.75), 2.18 (95%CI: 0.64, 7.48) respectively. Delaying ART appear to be potentially 
detrimental for the hazard of viral suppression: aHR: 0.98 (95%CI: 0.76, 1.26), 0.95, 
  iv
(95%CI: 0.73, 1.23), 0.84 (95%CI: 0.61, 1.15) for 15, 30, and 60 days delay 
respectively. 
Conclusion: Six-month weight gain and CD4 cell gain (count and CD4%) below the 
33rd percentile were equally strong predictors of poor ART outcomes suggesting that, 
pending construction of more generalizable charts, weight gain can be used in children 
on ART to discriminate those who are failing the treatment from those who are 
responding. Since delaying ART beyond 30 days appears to negatively affect both 
survival and viral response, the recommendation should be reevaluated and necessary 
delays should not exceed 30 days.  
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I. INTRODUCTION   
Worldwide, it is estimated that about 1500 new pediatric infections with the Human 
Immunodeficiency Virus (HIV) occur daily and more than 90% of those new 
infections are happening in sub-Saharan Africa [1, 2]. Children acquire HIV mainly 
through mother to child transmission [3].  In the absence of any intervention, between 
15% and 45% of infants born to mothers living with HIV will become infected (5–10% 
during pregnancy, 10–20% during labor and delivery and 5–20% through breastfeeding) 
[3]. Children who are infected earlier in life progress more rapidly to acquired immuno-
deficiency syndrome (AIDS) and death. In the absence of antiretroviral therapy (ART), 
more than a third of HIV-infected infants will not see their first birthday, and less than 
half will survive the first 2 years of life [4]. In high burden countries of Southern Africa, 
HIV is today the leading cause of death among children. In South Africa for example, 
more than 5% of children 5 years or younger are HIV infected [5] and HIV accounts for  
more than half of all deaths among children under the age of 5 years [6]. 
The spread of HIV worldwide has coincided with the re-emergence of 
Mycobacterium tuberculosis (TB) infections[7]. Despite the fact that TB is an 
important cause of childhood morbidity and mortality worldwide, TB in children has been 
less of a public health priority and data on trends in childhood TB are scarce in the 
published literature and marred with methodological limitations. In sub-Saharan Africa, 
more than anywhere else, HIV/TB co-infection has devastating consequences on chill 
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health. In some cross sectional studies of TB infected children in the region, HIV 
prevalence above 50% has been reported, compared to less than 5% in 
industrializedsettings [8-10]. The pathogeneses of both HIV and TB explain why HIV 
infection is such a fertile ground for TB.
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II. REVIEW OF THE LITERATURE 
A. Pathogenesis of HIV and TB co-infection 
1.   Pathogenesis of tuberculosis  
Tuberculosis is the world’s second commonest cause of death from infectious disease, 
after HIV/AIDS. There were an estimated 8–9 million new cases of tuberculosis in 2000 
[7]. TB is an airborne disease which is spread by droplet nuclei: particles of 1–5 µm in 
diameter that contain Mycobacterium tuberculosis. After expectoration by people with 
pulmonary or laryngeal tuberculosis during coughing, sneezing, singing, or talking,  the 
particles can remain airborne for minutes to hours [11]. Once the infectious droplet 
nuclei are inhaled, M tuberculosis is then taken up by alveolar macrophages, initiating a 
cascade of events that result in either a successful containment of the infection or 
progression to active disease (primary progressive tuberculosis) (figure I.1).  The T 
lymphocytes (particularly the CD4 positive T cells) are at the centre of this cascade. In 
fact, after being ingested by alveolar macrophages, M tuberculosis replicates slowly but 
continuously and spreads via the lymphatic system to the hilar lymph nodes. The 
infected macrophage releases interleukins 12 and 18, which stimulate T lymphocytes 
(predominantly CD4 positive T lymphocytes) to release interferon γ. In turn, interferon γ 
stimulates the phagocytosis of M tuberculosis in the macrophage. Interferon γ also 
stimulates the macrophage to release tumor necrosis factor α, an important factor in the 
granuloma formation. Activated T lymphocytes and macrophages form granulomas that 
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limit further replication and spread of the organism [11]. In most people (90%), unless 
there is a subsequent defect in cell-mediated immunity, the infection generally remains 
contained and active disease may never occur (fugure 1) [12]. However, when the host 
immune response cannot contain the replication of M tuberculosis associated with initial 
infection, either because of its immaturity as in young children or because of acquired 
immune deficiency as with HIV infection active disease occurs.  
 
Figure II-1. Transmission of tuberculosis and progression from latent infection to 
reactivated disease 
 
Source: [12] 
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2. Pathogenesis of HIV 
In children as in adults, the critical basis for the immuno-pathogenesis of HIV 
infection is the depletion of the helper/inducer subset of T lymphocytes which 
express the CD4 phenotypic marker (the CD4 cell). The CD4 lymphocyte is the focal 
and critical cell involved directly or indirectly in the induction of most immunologic 
functions [13]. HIV has a selective tropism for the CD4 cell. A convincing body of 
evidence has suggested that the CD4 molecule is, in fact, the high-affinity receptor for 
the virus [14]. After HIV binds to the CD4 molecule, the virus is internalized and 
uncoated. Once internalized, the genomic RNA is transcribed to DNA by the enzyme 
reverse transcriptase. The proviral DNA, which can exist in a linear or circularized form, 
is integrated into the host chromosomal DNA. After integration of provirus, the infection 
may assume a latent phase with restriction of the cycle until the infected cell is 
activated. Once cell activation occurs, the proviral DNA transcribes viral genomic RNA 
and messenger RNA. Protein synthesis, processing, and virus assembly occur with 
budding of the mature virion from the cell surface (figure I-2). When active replication of 
virus occurs, the host cell is usually killed. This results in progressive depletion of CD4 
cells with an expanded CD8 cell population, resulting in an inverted CD4/CD8 ratio. 
Removal of CD4 cells from the immune system renders it progressively weaker 
and unable to contain secondary infections and results in profound immune 
suppression [13, 14]. 
HIV infection in both children and adults causes a broad spectrum of diseases. In a 
meta-analysis of 17 studies in Europe and the United States of America, the most 
common AIDS events diagnosed were opportunistic infections (38%), followed by 
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serious recurrent bacterial infections (29%) and HIV encephalopathy (20%). The relative 
frequencies of these conditions were strongly age-related; Pneumocystis jiroveci and 
encephalopathy became proportionately less common, and serious recurrent bacterial 
infections proportionately more common, with increasing age. Pneumocystis jiroveci 
pneumonia (PCP) is a very common serious opportunistic infection in children with HIV-
1 infection and is associated with a high mortality [15]. The pneumonia most often 
manifests between 3 to 6 months of age in infants with vertically-acquired infection [16]. 
Primary and reactivated tuberculosis is a major cause of morbidity and mortality among 
HIV-1-infected children residing in communities where infection with the pathogen is 
endemic [15]. 
Figure II-2. The life cycle of HIV 
 
Link: http://www.medscape.com/content/2003/00/45/86/458640/art-nm458640.fig1.gif 
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B.  HIV-TB co-infection in children 
In general because of their immature immune system, children are highly susceptible to 
TB infection [17]. Following TB infection, children have a higher risk of progression to 
disease (extra-pulmonary and pulmonary) and death. Young infants have a particularly 
high morbidity and mortality from tuberculosis [17]. The effect of the HIV epidemic on 
the burden of tuberculosis in children has not been studied as well as in adults [7]. 
However, HIV is a major risk factor for childhood TB [18]. Children may contract both 
HIV and TB from a dually infected mother. Reported prevalence of HIV/TB co-
infection in children range from less than 5% in industrialized settings to over 50% in 
some high-burden countries of southern Africa [8-10]. In HIV/TB co-infected children, 
the poor cell-mediated immunity increases the risk for disseminated tuberculosis 
disease, especially in advanced stages of HIV infection, resulting in higher mortality 
compared to HIV-negative children infected with tuberculosis [19]. The risk of active 
tuberculosis in HIV co-infected children is related to CD4 count and indirectly to 
viral load [20] and restoration of cellular immunity with antiretroviral therapy 
reduces the susceptibility to tuberculosis [21]. 
C. Antiretroviral Therapy in children 
1.  Treatment objectives 
HIV causes a chronic infection which requires treatment for life once a child starts 
therapy. Current antiretroviral therapies do not eradicate HIV infection due to the long 
half-life of latently infected CD4 cells [22].  Antiretroviral therapy for HIV-infected 
children aims at reducing HIV-related mortality and morbidity, restoring and 
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preserving the immune function, maximally and durably suppressing viral 
replication, minimizing drug-related toxicity, maintaining normal physical growth 
and neurocognitive development, and improving the quality of life [22].  Today, six 
classes of antiretroviral drugs are available for HIV-1 therapy [23]. Two classes target 
the reverse transcriptase: the nucleoside reverse transcriptase inhibitors (NRTIs) and 
the non-NRTIs (NNRTIs). A third class – the protease inhibitors (PIs) target the viral 
protease. The newer classes: the fusion inhibitors, the entry inhibitors, and the HIV 
integrase strand transfer inhibitors are yet to be fully investigated in children [24]. Early 
results show enfuvirtide (fusion inhibitor) to be safe for long term use in children [25-29]. 
Currently, the treatment of choice for HIV-infected children is a combination of at 
least 3 drugs, which include at least 2 different classes of antiretroviral drugs [22, 24].  
2.  ART treatment in Children co-infected with TB 
Because of the risk of rapid progression and dissemination of TB, it is recommended 
that in children co-infected with HIV and TB, TB treatment be initiated as soon as the 
diagnosis of TB is suspected [24]. The duration of TB treatment may vary from 6 to 12 
months. Whatever the length of the treatment, rifampicin is recommended to be given 
for the entire duration [24]. Rifampicin reduces the serum concentrations of most 
PIs by 80% or more, and NNRTIs by between 20% and 60% [24]. Furthermore, the 
adverse events of anti-tuberculosis drugs and antiretroviral drugs are similar. For those 
reasons, it is recommended that initiation of ART in HIV-infected children with 
tuberculosis be delayed for at least 2-8 weeks after TB treatment initiation [24, 30]. The 
reason for the 2-8 weeks delay is to improve adherence and better differentiate potential 
side effects [30]. But the optimal timing of ART initiation in children co-infected with 
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HIV/TB is not known. The elevated incidence of TB and other secondary infections in 
HIV-infected children in sub-Saharan Africa coupled with the high pill burden (and the 
inherent challenge for adherence) and drug interactions underscore the need for strong 
monitoring of ART. 
3. Monitoring of ART treatment 
The prime target of antiretroviral drugs is the blocking of viral replication at multiple 
points in the viral life cycle (figure II-2). A quantitative and direct measure of the 
effectiveness of ART is the amount of viral particles that can be found in the various 
compartments of the body. The most commonly used of such measures is the plasma 
viral load. In clinical trials as well as in clinical practice, following initiation of ART, 
treatment effectiveness is measured as a substantial and sustained decrease in plasma 
HIV RNA concentration  [21, 31-35]. Effectively blocking viral replication stops the 
depletion of CD4 cells and results in progressive increase in the absolute count of those 
cells as well as the re-equilibration of the CD4/CD8 ratio [31-39]. The monitoring of 
pediatric ART in developed nations typically consists of the evaluation of CD4 
count and viral load every 3-4 months [22]. However, the measurement of viral load 
and/or CD4 cells count requires expensive and sophisticated technologies that cannot 
always be easily transferred to or sustained in all resource-limited settings.  
HIV-infection has a severe negative effect on both height and weight gain in 
children. In the postnatal period, growth of HIV-infected children rapidly lags behind 
that of HIV-uninfected children. Decrements in both linear and ponderal growth are 
detectable by the age of 3 or 4 months [40]. This slow growth is sustained throughout 
childhood. In a prospective study of 282 term infants born to HIV-infected women in 
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USA, Moye et al. found that HIV-infected children were 0.7 kg lighter and 2.2 cm shorter 
than HIV-exposed but uninfected children at 18 months of age [41]. Similarly in a 
retrospective study, Arpadi et al. found that 42% (14 of 33) of perinatally HIV-infected 
children >5 years old had a growth velocity of less than the 5th percentile (mean growth 
rate, 3 cm/year), an indication of severe growth failure [42]. Newell et al. also reported 
that by the age of 10 years, uninfected children in Europe were on average an 
estimated 7 kg heavier and 7.5 cm taller than infected children [43]. The mechanism 
through which HIV infection results in growth failure in children is complex and not well 
understood. However, initiation of effective ART results in substantial but 
heterogeneous improvement in somatic growth. In a previous analysis of data from 
2102 children from our cohort in Soweto, South Africa, we found that initiation of ART 
was followed by a catch-up period of rapid growth of about a year (figures II-3) after 
which the average weight and height Z scores stabilized close to but below the 
expected mean of zero [37]. Younger children gained more substantial weights and for 
a longer period than older children. Similarly in a prospective cohort of 192 USA infant 
24 months or younger, Nachman et al. found that younger children gained height more 
rapidly and children with greater baseline viral loads gained weight more rapidly [44].  
Futhermore, in a retrospective analysis of a cohort of 1212 European children, Guillen 
et al. reported that  children who successfully suppress viral replication have 
significantly higher z-score for weight and height [45]. In a retrospective analysis of 
cohort of 749 HIV-infected children receiving care in Uganda with average baseline 
weight-for-age z-score (WAZ) and height-for-age z-score (HAZ) of -3.2 and -2.7 
respectively, the authors reported that children gain weight more rapidly than height 
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[46]. The ART regimen itself affects growth. In a prospective study comparing protease 
inhibitor (PI) and non PI containing regimens in 906 HIV-infected children in the United 
States with average baseline WAZ = -0.42 and HAZ = -0.90, the authors reported that 
the use of PIs was associated with per-year gains of 0.13 z scores in height and 0.05 z 
scores in weight relative to the expected growth with non–PI containing regimens [47]. 
The strong somatic growth observed after ART initiation and the fact that weight and 
height are relatively easy to measure make them a good alternative to viral load or CD4 
count for the monitoring of ART. 
In resource poor settings where viral load or CD4 cells count are not available, the 
WHO recommends that primarily clinical parameters be used for monitoring ART, 
particularly the improvement in somatic growth in children who have been failing to 
grow [24]. 
However, the problem with using somatic growth and to some extent CD4 cell 
count and CD4% as monitoring tools for ART in children is that the velocity at which 
children gain weight, height, and CD4 cells strongly depends on age or gender. 
Therefore, reference value ranges change with age and/or gender making the 
development of simplified protocols very difficult. A major limitation with standardized 
growth is that parameters from a reference population are needed for its calculation. In 
addition that measurements from patients have to be converted to standard values 
before they can be used, currently the available standards are cross-sectional and do 
not measure the velocity of somatic growth in HIV-infected children on ART [48, 49]. 
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Figure II-3. Change in the average height- and weight-for-age z score in a cohort of 
2102 children who received ART at the Harriet Shezi Children’s clinic between April 
2004 and March 2008 
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So far, to our knowledge, all studies [41, 50-54] but one [55] that have assessed the 
usefulness of somatic growth as prognostic tools for HIV/AIDS disease progression or 
as a monitoring tool for ART response employed standardized growth.  
In the study by Carey et al. using observations from 1338 HIV-infected children aged 3 
months to 15 years who participated in one of four US clinical trials of pediatric anti-HIV 
therapies, the authors used statistical smoothing (locally weighted regression) of growth 
histories to derive velocity estimates, and used quantile regression to determine the 
distributions of physical growth velocities. Using the obtained distributions, the authors 
show that they could be used to predict HIV progression. But, children in the study were 
North American who were either on mono or dual therapy or not on ART at all [55].  
D. Summary 
In summary, of the 2 million children living with HIV worldwide, more than 90% are in 
sub-Saharan Africa where the epidemic of HIV is compounded by that of TB. In some 
high-burden countries of Southern Africa, more than 50% of TB-infected children are 
also HIV-infected. Despite the increasing availability of ART on the continent, the high 
pill burden and its potential negative effect on adherence, coupled with substantial drug 
interactions between anti-tuberculosis and antiretroviral drugs complicate the 
management of HIV/TB co-infection and call for closer monitoring of ART in those 
settings. But, frequent viral load and CD4 measurements that are standard for 
monitoring ART in developed countries are not always available or sustainable in some 
of the poorest regions. Alternative means for monitoring the response to ART that are 
easy to use and do not rely on sophisticated technologies are needed. In addition 
because of the drug interactions between anti-TB and antiretrovirals, it is currently 
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recommended to delay ART for at least 2 to 8 weeks after TB treatment initiation in 
HIV/TB co-infected children. But the effect of this delay on survival and response to 
ART as well as the optimal timing of ART initiation among those children are yet to be 
determined.
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III. STATEMENT OF SPECIFIC AIMS 
A. Study questions/specific aims 
Research question 1: How much weight, height, or CD4 cell count (both absolute and 
percentage) gain in the first 6 months of ART is an indication of good ART response in 
HIV-infected children?  
 
Specific aim 1: To construct reference distribution for the first 6-month weight, height, 
absolute CD4 count, and CD4% gains and assess the value of the 3rd, 10th, 25th, 33rd, 
and 50th percentile of each distribution as predictors of death, virological suppression, or 
treatment failure after 6 months of ART. 
 
Research question 2: What is the optimal timing for ART initiation in HIV/TB co-
infected children? 
 
Specific aim 2: To determine the effect of delaying ART initiation after TB treatment 
initiation in HIV/TB co-infected children on virological suppression and survival 
respectively. 
B. Hypotheses 
Hypothesis for Aim 1 
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 Children falling below the 3rd, 10th, 25th, 33rd, or 50th percentile of weight, height, CD4 
cell gains at 6 months post-ART are at higher hazard of death, of not achieving viral 
suppression, or of failing antiretroviral treatment subsequently. 
 
 
Hypothesis for Aim 2 
In HIV/TB co-infected children, initiation of ART immediately after TB treatment will 
improve survival but decrease subsequent virological response to ART. 
C. Rationale 
Rationale for aim 1 
The high pill burden and drug interactions between ART and other anti-infectious agents 
demand that children initiated on ART in the region, be closely monitored. But, frequent 
viral load measurements that are the standard for monitoring ART in developed 
countries are not always available in some of the poorest settings. Alternative means for 
monitoring ART that do not rely on sophisticated technologies are needed. Somatic 
growth and to some extent CD4 cell count have been recommended for use in those 
settings. But because, the absolute gain in weight, height, and CD4 count following ART 
initiation are strongly dependent on age or gender, reference distributions have to be 
constructed and cut-off points for decision making defined. The 6-month interval was 
chosen to match to the current recommended interval for repeating viral load and CD4 
count and in accordance with the published literature covering growth velocity and HIV 
prognostic [55-57]. 
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Rationale for aim 2 
In sub-Saharan Africa where more than 90% of HIV-infected children worldwide live, 
prevalence of HIV among TB-infected children top 50% in some high burden countries. 
Despite increasing available of ART, this high prevalence of HIV/TB co-infection and 
substantial drug interactions that exist between anti-TB and ART have complicated the 
management of pediatric HIV in the region. Currently, though the recommendation is to 
delay ART initiation for at least 2 to 8 weeks after TB treatment initiation, the optimal 
timing of ART in those children is not known. The justification for the 2-8 weeks delay is 
to at least be able to distinguish side effects due to anti-TB from that due to ART drugs 
and therefore to improve adherence to ART and the virological response. Knowing the 
effect of currently recommended delay on survival and virologic suppression can help to 
improve the management of HIV/TB co-infected children.
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IV. METHODS 
A. Overview of methods 
For aim 1, the Generalized Additive Model for Location, Scale and Shape (GAMLSS) 
and the Box Cox Power Exponential (BCPE) distribution were used to construct the 
distribution of 6 months post-ART initiation weight, height, CD4 cell count, and CD4% 
gains and the Cox proportional model was used to assess the association of the 
selected centiles of each distribution with the 3 outcomes considered.  
For aim 2, the inverse-probability-of-treatment weighting method of marginal structural 
model was used to adjust for time-varying confounding by indication and potential lead 
time bias for the effect of ART delay on survival. Multivariate Cox model was used to 
assess the effect of ART delay on viral suppression.  
B. Design 
1. Data source 
a. Study site 
The data used in these analyses are from an observational clinical cohort of HIV-
infected children who sought and received care at Harriet Shezi Children’s Clinic 
(henceforth the clinic) from April 1st, 2004 to March 31st, 2008. The clinic is a pediatric 
outpatient HIV clinic at Chris Hani Baragwanath Hospital (the hospital) in Soweto, South 
Africa. It was started in 1997 by Dr Tammy Meyers and later became known as the 
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Harriet Shezi Children’s Clinic in 2000. The name Harriet Shezi was chosen in 
recognition of the first black matron of the hospital appointed in 1958, a symbol of 
triumph in the face of adversity and prejudice. While it is a government service, funding 
and support from international agencies including the United States President's 
Emergency Plan for AIDS Relief (PEPFAR), the United Nations Children's Fund 
(UNICEF), Elizabeth Glazer Pediatric AIDS Foundation, Rockefeller Brother’s Fund, the 
South African business sector and a host of individuals, schools and churches, have 
allowed the clinic to expand in response to the community’s need for quality 
comprehensive pediatric HIV care services. This support enabled the antiretroviral 
treatment of children with AIDS even before free ART became available in the public 
sector. On April 1st, 2004 the South African government launched a massive program to 
roll out ART throughout the country with the ambitious goal of providing ART to all its 
HIV-infected citizens in need. The clinic was among the firsts to start HIV-infected 
children on ART [58]. As of March 2008, more than 3553 HIV-infected children have 
received care in the clinic among whom about 2216 had been initiated on ART in the 
government program, making it the largest pediatric HIV clinic in South Africa and one 
of the largest in the world. Harriet Shezi Children’s Clinic has, since the year 2000, been 
an international research site for the International Maternal Pediatric and Adolescent 
AIDS Clinical Trials Network (IMPAACT), formerly known as the Pediatric AIDS Clinical 
Trial Group (PACTG). 
b. Study population 
Children in the clinic are referred primarily from the pediatric ward of the hospital, 
though referrals from other sites and services do occur. To be enrolled in the clinic, 
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documented HIV-infection is required. Because children who received HIV care before 
ART became free in the country might be different from those who accessed HIV care 
after April 2004, all analyses were restricted to children whose initial visit in the clinic 
occurred between April 1st, 2004 and March 31st, 2008.  For aim 1, children had to have 
at least 6 months of follow-up on ART, a pre-ART measurement of either weight, height, 
CD4 count, and CD4% and another measurement between 5 and 7 months (needed to 
calculate the 6 months gain) (figure IV-1). For aim 2, they needed to have been initiated 
on TB treatment in the clinic before ART (figure IV-2). Children older than 15 years were 
excluded from all analyses. 
Figure IV-1. Description of the cohort of children who received ART at Harriet Shezi 
Children’s Clinic between April 2004 and March 2008 and had both baseline and 6 
months post-ART initiation measurements for either weight, height, and CD4 cell count 
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Figure IV-2. Description of the cohort of ART naïve children who were initiated on TB 
treatment at Harriet Shezi Children’s clinic between April 2004 and March 2008 
 
 
 
c. Treatment protocols 
At the initial visit to the clinic, HIV-infected children were assessed for their clinical 
history and physical examination and their WHO clinical stage was determined. Children 
were initiated on ART and follow-up according to the national guidelines: an adaptation 
from the WHO guidelines for ART in children [57]. The first line regimen included 
stavudine, lamivudine, and ritonavir boosted lopinavir (LPV/r or Kaletra®) for children 
younger than 3 years of age or efavirenz for those over 3 years and over 10kg of 
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weight. Second line regimen included zidovudine, didanosine, and nevirapine for 
children 3 years or younger or Kaletra®/efavirenz for children older than 3 years. 
Children who were started on ART were clinically reevaluated at 1 month, at 3 months, 
and every 3 months thereafter or at any other time if clinically needed. However, the 
pharmacy dispensed a maximum of 2 month’s supply of medication.  
Children attending the clinic were routinely screened by clinicians for TB and other 
opportunistic infections prior to initiating antiretroviral therapy. In accordance with 
national pediatric guidelines [58], all children should have had a chest X-Ray, induced 
sputum or gastric washings for TB microscopy, culture and sensitivity and a tuberculin 
skin test (TST). In the clinic, TB was commonly diagnosed on clinical grounds including 
severe failure to thrive, prolonged (more than two weeks history of) cough, suspicious 
chest radiograph with or without a positive contact history or bacteriological diagnosis. 
Children with these features were often commenced on TB treatment prior to ART 
initiation even in the absence of a definitive TB diagnosis.  Children with TB were 
treated according to national guidelines with a combination of rifampicin, isoniazid, and 
pyrazinamide for the initial 2 months followed by rifampicin + isoniazid for the remaining 
4 months [59]. In children with TB diagnosed before ART, it is recommended ART be 
delayed for 4 to 8 weeks. The guidelines allowed ART to be started earlier in severe 
cases.  
d. Data collection, Laboratory procedures, database, and defaulter tracing 
Clinical information was collected at every scheduled visit and laboratory investigations 
(hematology, chemistry, viral load, and CD4 cell count) were done at baseline and at 
the 6-monthly visit unless otherwise indicated. Laboratory tests were conducted at the 
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central laboratory of the Chris Hani Baragwanath Hospital which is part of the National 
Health Laboratory Services. HIV was diagnosed using two ELISA tests for children 18 
months or older; a polymerase chain reaction (PCR) was used to detect HIV-1 proviral 
DNA for younger children. Plasma viral loads were initially measured using The 
AMPLICOR HIV-1 MONITOR Test, v1.5 (Roche) with lower limits of detection at 400 
RNA copies/ml and the upper bound at 750,000 RNA copies/ml and subsequently a 
NASBA based viral load assay (Nuclisens EasyQ, Biomerieux) with lower and upper 
limits of detection at 25 and 3 million RNA copies/ml. CD4 counts were measured using 
a flow cytometer (Beckman Coulter). 
To track program performance indicators and appointment attendance, a locally 
developed electronic medical record was used to record patients’ data. At the end of 
each clinic day, an on-site team of data capturers entered designated elements from 
clinical forms into the database. In addition, a list of patients who missed clinic 
appointments was generated and given to a full time on-site defaulter tracer who 
contacted them by phone (about 75% of kids/family members had a phone). In case a 
patient could not be contacted by phone, a home visit was scheduled. The outcome of 
the tracing and reasons for missed visits were recorded in the electronic record.  
e. Data cleaning and Quality control 
Between June and August 2007, the electronic database was reviewed for it 
completeness. Particular entries such as weight, height, CD4 count, viral load were 
compared to medical records and any mismatches between the information in the 
electronic database and the medical records were investigated. Data capturers and data 
managers were closely associated in this process and have continued this process on a 
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regular basis to ensure consistency of values in the electronic database and the medical 
records. From March 31st 2008, when the dataset was closed for this analysis and June 
2008, the process was repeated again and any unreasonable value was resolved.   
2. Method for the proposed Aims 
a. Classification of exposure 
1. Exposures for aim 1 
Four exposures were considered in this analysis: the 5th, 10th, 33rd, and 50th percentile 
of the distribution of weight, height, absolute CD4 cell count, and CD4% gain in the first 
6 months post-ART initiation. We used a 6-month interval to match the recommended 
interval for viral load or CD4 count measurements for monitoring purposes in the clinic 
and in accordance with the published literature covering growth velocity and HIV 
prognostic [55-57]. 
2. Exposure for aim 2 
The main exposure considered for aim 2 was time from TB initiation to ART initiation 
categorized in 15, 30, and 60 days or less and greater (delayed ART). The 15, 30, and 
60 days cut-offs were chosen to approximate the minimum 2-8 or 4-8 weeks delay 
between TB treatment initiation and ART recommended in the WHO or the South 
African guidelines [24, 57]. 
b. Classification of outcomes 
Three main outcomes were considered in these analyses: time to death (survival), time 
to first virological suppression and time to treatment failure. For children whose exact 
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date of death was missing, the date of last visit in the clinic was used as date of death. 
Time to first virological suppression was defined as the date of the first viral load 
measurement below 400 HIV RNA copies/ml (virological suppression). Treatment failure 
was defined as either failure to achieve virological suppression after at least 1 year of 
HAART, failure to achieve virological suppression prior to switch to second line regimen, 
or 2 viral load measurements above 1000 RNA copies/ml after initial viral suppression. 
The third outcome was only considered for aim 1. 
3. Data analysis 
a. Descriptive statistics  
The distributions of baseline (ART initiation for aim 1 or TB treatment initiation for aim 2) 
characteristics were compared between the outcomes or exposures categories using 
Pearson chi square for categorical variables.  For continuous variables, an unpaired, 2-
tailed t-test was used if the normal assumption held or Wilcoxon rank sum (Mann-
Whitney) test otherwise. The normality assumption was empirically tested using the 
Kolmogorov-Smirnov test [60].  
 
Kaplan-Meier curves were fitted to examine survival or failure functions of the 3 
outcomes stratified by the exposures and baseline characteristics: sex, CD4 cell count 
(categorized according to WHO immune suppression classification [24]) in mild or not 
significant, advanced, and severe), WHO clinical stage (Stage I&II vs. III&IV), Weight-
for-age z-score (categorized as <-3SD, -3 to -2SD, and >=-2SD), Viral load categorized 
at about its median, TB treatment, and age at initiation of ART categorized < 18 months 
and 18 - 35 months, 36 – 59 months, and 60 months and above at baseline. The cut 
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offs for age were chosen not only to match the treatment indication cut off and the 
published conventions, [61] but also to capture the variation in the mortality rates by 
age. Gender specific weight-for-age and height-for-age z score (WAZ and HAZ) were 
plotted against WHO growth charts for children younger than 5 years and against US 
Centers for Disease Control and Prevention (CDC) charts for children 5 years or older, 
because WHO charts were not available for older children [49, 62]. Log-rank test was 
used to assess if the time-to-event differs statistically among the stratification 
groups.[63] 
b. Statistical modeling 
1. Modeling for aim 1 
Estimation of the amount of weight, height, CD4 cell count, and CD4% gained in 
the first 6 months of ART 
Biological and measurement variations between 2 consecutive measurements of weight 
and height, CD4 and CD4% can be important (figure IV-2, IV-3, IV-4). To minimize 
those variations, locally weighted quadratic regression was used to smooth the pattern 
of change in height, weight, and CD4 measurements over time after ART initiation for 
each individual. Locally weighted scatterplot smoothing (LOWESS) regression is an 
extension of the locally estimated scatterplot smoothing (LOESS) model [64] that 
performs linear regression on points in a data set weighted by a kernel centered at each 
given point X = x (in our case at each age point in the data).  The estimated response 
curves: Hi(t), Wi(t), and Ci(t) for weight, height, and CD4 (both absolute and 
percentage), where t represents any chronological age (in years) within the limits of 
observed follow-up time on the ith participant were obtained for each individual child 
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(figure IV-2, IV-3, IV-4). The 6-month gain estimates were simply calculated as the 
differences Hi (ti0 + 6) - Hi (ti0), Wi (ti0 + 6) - Wi (ti0), and Ci (ti0 + 6) - Ci (ti0), for weight, 
height, and CD4 respectively.  
 
Figure IV-3. Weight response curves over chronologic age following ART initiation for 4 
HIV-infected children estimated using locally weighted regression. 
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Figure IV-4 Height response curves over chronologic age following ART initiation for 4 
HIV-infected children estimated using locally weighted regression 
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Figure IV-5. CD4% response curves over chronologic age following ART initiation for 4 
HIV-infected children estimated using locally weighted regression. 
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Figure IV-6. CD4 cell count response curves over chronologic age following ART 
initiation for 4 HIV-infected children estimated using locally weighted regression. 
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Construction of age-specific reference distributions for the estimated 6 month 
gain in weight, height, CD4, and CD4 percentage 
Growth curves have typically been constructed based on the assumption that heights, 
weights, and other similar measurements, are normally distributed. Age-specific mean 
and standard deviation curves, µ(t) and σ(t), are estimated and any chosen quantile 
curve for τ in the interval [0, 1] can then be constructed as  
)()(ˆ)(ˆ)|(ˆ 1 ttttQ −Φ+= σµτ  
Where )(1 t−Φ  denotes the inverse of the standard normal distribution function. Provided 
that observation are normally distributed at each age (t), these curves split the 
population into two parts with the proportion τ lying below the curve, and the proportion 
1 - τ  above the curve [65].   
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In children, the distribution of weight, height, or CD4 cell gain can be quite non-normal. 
To overcome this challenge, Cole and Green in 1992 proposed the Lambda, mu, and 
sigma (LMS) method [66]. For this method, the distribution at each covariate value is 
summarized by three parameters, the Box-Cox [67] power λ, the mean (median) µ, and 
the coefficient of variation σ, and the initials of the parameters give the name to the LMS 
method. To avoid grouping the data according to the value of covariate (in our case 
age), the method of maximum penalized likelihood is used to provide smooth estimates 
of the L, M and S curves directly with the three parameter constrained to change 
smoothly as the covariate changes.   
However, this method assumes an underlying skewed normal distribution of the 
measurements so that a suitable power transformation [67] would render the distribution 
normal. The main problem with skewed normal distribution is the presence of kurtosis 
as the power transformation does not adjust for it. Although kurtosis is less important 
than skweness as contributor to non-normality, its presence can bias the estimated 
distribution. In the recent years, the LMS method has been expended to control for 
kurtosis with the introduction of Box-Cox power exponential (BCPE) distribution [68].  
The BCPE distribution denoted BCPE (µ, σ, υ, τ), is a model for dependent variables Y 
exhibiting both skewness and kurtosis. The distribution is defined by a power 
transformation of Y (Yυ) having a shifted or scaled standard power exponential 
distribution with parameter τ. So in addition to the 3 parameters of the skewed normal 
distribution, a fourth parameter is added for the BCPE distribution [68]. The BCPE 
distribution is also referred to as LMSP and has been adopted by the WHO as reference 
method for constructing the international growth curves [69].  
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LMS and LMSP are semi-parametric methods in the sense that to fit the models, a 
parametric distribution of Y has to be specified. Alternative methods to construct 
reference distributions that do not require any assumption on the parametric distribution 
of Y to be specified include non-parametric quantile regressions. In cases where 
transformation in semi-parametric methods can normalize the distribution of Y, results of 
the LMS or LMSP methods and non-parametric quantile regressions are comparable 
[65]. However, contrary to the semi-parametric methods, spacing between curves from 
non-parametric quantile regressions are not constrained to be related to each other and 
adjacent curves may cross, particularly at the ends of x axis. For this reason and 
because LMSP is the method of reference use by WHO, we chose the semi-parametric 
quantile regression method with BCPE as the parametric distribution for the 
construction of the distribution of 6-month gain in weight, height, CD4 count and CD4% 
and estimation of centile curves.  
The generalized additive model for location, scale and shape (GAMLSS) was used to fit 
the chosen BCPE (µ, σ, υ, τ) distribution and estimate its different parameters with age 
at 6 month post-ART as explanatory variable. A GAMLSS assumes independent 
observations yi for i = 1; 2; …; n with probability (density) function )|( iiyf θ conditional 
on iθ  = ( i1θ ; i2θ ; i3θ ; i4θ ) = ( iµ ; iσ ; iν ; iτ ) a vector of four distribution parameters, each 
of which can be a function to the explanatory variables.  The first two parameters 
( iµ ; iσ ) are location and scale parameters, and the two remaining if any, are the shape 
parameters (skewness and kurtosis). The form of the distribution assumed for the 
outcome Y, ),,,|( iiiiiyf τνσµ is very general and the gamlss package in R can fit a 
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number of distributional families (including the BCPE) for both discrete or continuous 
variables [70, 71]. GAMLSS allows all the parameters of the distribution of the response 
variable Y to be modeled as linear or non-linear (smooth) functions of the explanatory 
variables. In this analysis all parameters were modeled as cubic splines function of age. 
To specify the GAMLSS model, in addition for choosing the family distribution for the 
response variable, the user has to choose the smoothing constant or degrees of 
freedom for each of the parameter in the model that is specified as a function of 
explanatory variables. The process for choosing those constants can be subjective and 
cumbersome. Rigby & Stasinopoulos propose a 3 steps systematic approach [68]. In 
the first step, the appropriate power for transforming the explanatory variable to improve 
the general fit of the model is considered. In this study, to simplify the interpretability of 
the constructed curves, we did not transform age, thought its transformation in some 
cases improved the fit substantially. In step two, taking one parameter at a time, the 
number of degrees of freedom for the smoothing constant for the parameter that 
minimize the generalized Akaike Information Criterion (GAIC) (a measure of global fit of 
the model) is selected. The last step is used to fine tune those numbers of degrees of 
freedom.  
The best set of the combination of effective degrees of freedom obtained was used to fit 
the final model and the Q-statistic [72] and worm plots [73] were used for the diagnostic 
of potential region-wise and overall misfit (Appendice B).  
The main assumption of the BCPE regression model is that after the appropriate 
transformations, the distribution of outcome is normally distributed independently of age. 
Therefore, residuals are expected to have a normal distribution that can be evaluated 
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using the usual residuals plots. However, the residual plots are not powered to detect 
age related departure from the model (i.e. a poor fit of the model at a given age point). 
The Q-statistic [72] and worm plots [73] have been proposed to this end. For Q-test, age 
is categorized in groups of approximate equal size and the Q-test statistics which are 
sensitive to age dependency are computed for the first four moments, z1, z2, z3, z4: 
values larger than 2 indicate a misfit of respectively the mean, variance, skewness, and 
kurtosis. The worm plot is a collection of detrended Q-Q plots, each of which applies to 
one of successive age groups. The data plot in each plot form a worm-like string. The 
shape of the worm indicate how the data differ from the assumed underlying distribution 
[73]. A flat worm indicates a good fit (Appendice A).  Correction of those point-wise 
misfits were attempted by fine tuning the number of degree of freedom for the 
corresponding parameter [68].  
 
Assessing the association between the weight gain and subsequent response to 
ART. 
Cox proportional hazard models were used to estimate the effect of each of the selected 
centiles, adjusted for baseline characteristics. The main assumption of the proportional 
hazard model is that the hazard in the index group is proportional to the hazard in the 
referent group [74]. This proportional hazard assumption was formally evaluated for all 
covariates using the Kolmogorov-type supremum test [75]. All available baseline 
characteristics were entered in the full model for each of the chosen centile and using a 
backward selection procedure all variables that did not contribute significantly (Wald test 
p-value >0.05) to the fit of the model were dropped from the final model.  
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2. Modeling for aim 2 
In aim 2, we wanted to estimate the effect of initiating ART within the first 15, 30, or 60 
days of TB treatment initiation on mortality and virological response. The problem with 
this was that, though per guidelines, all children with TB are eligible to ART, the 
decision whether to initiate or delay ART for a given child was made at each visit based 
on clinical and immunological characteristics of the child at the visit. Hence children in 
advanced clinical stage who were more likely to die were initiated on ART earlier while 
initiation was delayed for those in better clinical status (figure IV-6). This introduces a 
time-dependent confounding by indication in the analysis.  In addition, some children in 
who ART initiation was delayed could have died before they could be properly classified 
for exposure (i.e before they had at least 15, 30, or 60 days of follow-up after TB 
treatment). To adjust for this confounding and the potential lead time bias, we used 
inverse-probability-of-treatment weighting (IPTW) of marginal structural model [76-78].  
The IPTW is an extension of the Horvitz-Thompson estimator. Stated in non 
mathematical terms, the Horvitz & Thompson estimator stipulates that for each 
probability sample (sample with known non zero probability of selection for each 
element), an unbiased estimate of the population mean or total can be obtained by 
weighting each observation in the sample by the inverse of its probability of selection 
[79]. The Horvitz-Thompson was subsequently expanded to any population parameter 
including regression coefficients  [80]. Applications of the Horvitz-Thompson estimator 
are common in the causal inference literature [78, 81, 82]. However, contrary to surveys 
where the probabilities of selection are fixed and assumed to be known, in observational 
studies, these probabilities have to be estimated from the sample at hand using 
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measured covariates and mathematical modeling. This means that the resulted weights 
can be highly instable and the validity of the estimator depends on non verifiable 
assumptions such as no misspecification of the models for weights and no unmeasured 
confounding [78]. To limit the variability of the estimated probabilities or weights, Robins 
proposed using “stabilized weights” instead in the IPTW estimator [78]. 
To estimate the stabilized weights [83], time from TB treatment initiation to ART was 
treated as failure time and was categorized as less than 0.5 month, 0.5-1, 1-2, 2-3, 3-4, 
4-5, 5-6, and 6 months of greater. The cut-off was chosen to match that of exposure 
and to ensure that there were enough observations in each interval to fit the models. 
For the numerator of stabilized weights, a pooled logistic model for the probability of 
initiating ART in each time interval was specified with severity of immunosuppression, 
log viral load, WAZ, and age at TB treatment initiation as fixed covariates. For the 
denominator, the same pooled logistic model as above was specified with severity of 
immunosuppression, log viral load, and WAZ as time-varying covariates. Apart from the 
initial visit, if a patient had more than 1 measurement for a time-varying covariate in a 
time interval, only the last measurement was considered. A necessary condition for 
correct model specification is that the stabilized weights have a mean of one [83]. 
Estimating the effect of ART timing on ART outcomes 
Using the estimated stabilized weights, weighted Cox proportional models were fitted to 
obtain the crude and adjusted effect of the timing of ART initiation on survival or on 
virological suppression. All covariables included in the models were formerly assessed 
for the proportional hazard assumption using the Kolmogorov-type supremum test.[75] 
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All analyses were conducted using SAS 9.1 (SAS Institute, Cary, NC) and all tests were 
conducted at 0.05 significance level. 
 
Figure IV-7. Directed acyclic graph for the effect of ART delay on survival among 
HIV/TB co-infected children 
 
 
Figure IV-8. Directed acyclic graph for the effect of ART delay on virological 
suppression among HIV/TB co-infected children 
 
Vk = visit k, where k = 0,1,2, … n  from TB treatment initiation, tk = time from TB treatment initiation to visit k. 
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V. SIX-MONTH POST-HAART INITIATION GAINS IN WEIGHT, HEIGHT, AND CD4 
COUNT AND SUBSEQUENT MORTALITY AND VIROLOGIC RESPONSE IN HIV-
INFECTED SOUTH AFRICAN CHILDREN 
A. Introduction 
More than 2 million children live with HIV worldwide and more than 90% of them live in 
sub-Saharan Africa.[1]  In the absence of antiretroviral therapy (ART), a third of children 
infected perinatally will not survive to their first birthday, and more than half will not 
survive their second birthday.[4] Despite recent international efforts to increase access 
to ART in low and middle income countries, the scaling up of ART in sub-Saharan Africa 
faces at least two major challenges. 
First, in developed nations, the monitoring of ART consists of evaluating CD4 count and 
viral load every 3-4 months.[22] However, the measurement of viral load and CD4 cells 
count requires expensive and sophisticated technologies that cannot always be easily 
transferred or sustained in some of the poorest settings. In settings where viral load or 
CD4 cells count are not available, the World Health Organization (WHO) recommends 
that clinical parameters be used for monitoring ART, particularly the gains in weight or 
height in children.[24]  
Second, in addition to the lack of the infrastructures, sub-Saharan Africa also faces an 
enormous shortage of trained health care personnel.[84] In the context of efforts to 
rapidly increase access to HIV services, the WHO recommends that specific tasks be 
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moved, where appropriate, from highly qualified health workers to health workers with 
shorter training and fewer qualifications.[85] For this task shifting to be efficient, 
simplified protocols with clear decisional algorithms must be available. Contrary to viral 
load, which has a clear and simple target cut-point (below detection limit), cut-points for 
weight, height, and CD4 cell gain that correlate with subsequent treatment outcomes 
have not been clearly established.   
In this study, we aimed to construct percentile curves for gains in weight, height, 
absolute CD4, and CD4% in the first 6 months of ART, and to test the value of the lower 
centile curves (3rd, 10th, 25th, 33rd, and 50th) as predictors of subsequent death, 
virological suppression, or treatment failure.  
 
B. Methods 
During the first 4 years (April, 2004 to March, 2008) of government sponsored HIV 
treatment and care program for HIV-infected children at  the Harriet Shezi Children’s 
Clinic, a pediatric outpatient clinic at Chris Hani Baragwanath Hospital, Soweto, 
Johannesburg, 2193 children 15 years or younger were initiated on ART. Of these, 
1549 (70.6%) had at least 6 months of follow-up on ART and 1394 (90.0%) with 
baseline and 6 months follow up weight, height, absolute CD4, and CD4% data  were 
included in this analysis. ART eligibility was in accordance with national guidelines [57]. 
The first line regimen included stavudine, lamivudine, and ritonavir-boosted lopinavir 
(LPV/r) for children 3 years or younger; or stavudine, lamivudine and efavirenz for those 
over 3 years and over 10kg of weight. Second line regimen included zidovudine, 
didanosine, and nevirapine for children 3 years or younger; zidovudine, didanosine, and 
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LPV/r or efavirenz for children older than 3 years. Children who were started on ART 
were clinically reevaluated at 1 month, at 3 months, and every 3 months thereafter or at 
any other time if clinically needed.  
At each scheduled visit, children were assessed clinically and weight and height 
(children 2 years or older) or length (children < 2years) were recorded. Laboratory 
investigations (hematology, chemistry, viral load, and CD4 cell count) were done at 
baseline and every 6 months unless otherwise indicated.  
Statistical Analysis 
Construction of percentile curves of the 6-month gains in weight, height, CD4, 
and CD4%  
For each individual child, with n sequence data of weight, height or length, CD4 count, 
and CD4% measurements, the response curves were obtained by smoothing the n 
measurements over the chronological age at the time of the measurement using locally 
weighted quadratic regression. The 6-month estimates of weight, height, CD4, and 
CD4% gain were obtained by subtracting the response curve estimates at 6 months 
from the estimates at ART initiation. [86] 
To obtain the reference percentile curves, we used methods similar to those used by 
the WHO to construct recent international growth curves. [69] The 6-month estimates of 
weight, height, CD4 count, and CD4% gain were regressed on chronological age using 
the generalized additive model for location, scale and shape, a method that requires a 
parametric distribution assumption for the response variable while allowing the modeling 
of the distribution parameter as nonparmetric (smooth) functions of the explanatory 
variables [87]. For the response variable, we assumed a Box-Cox power exponential 
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distribution with four parameters relating to location (µ, median), scale (σ, coefficient of 
variation), skewness (υ, transformation for symmetry), and kurtosis (τ, power 
exponential parameter), respectively[68]. To specify the model, the user must choose 
the number of degrees of freedom (df) to be used for each parameter. Starting with the 
simplest model that includes age and the fitting of µ and σ curves while keeping the 
degree of freedom for υ and τ fixed at zero, we searched for df(µ) and then df(σ) that 
minimized the global deviance as indicated by the generalized Akaike Information 
Criterion (with penalty 3 for each degree of freedom used). In the next step, using the 
df(µ) and df(σ) selected in the previous, we sequentially searched for the df(υ) and df(τ) 
that minimized the global deviance. In the last step, Q statistic [72] and worm plots [73] 
were used to fine tune the selected df(µ), df(σ), df(υ), and df(τ) [68].  
The selected optimum set of degrees of freedom was used to fit a final model and the age-
specific mean and standard deviation curves, µ(t) and σ(t), were estimated. Centile curves for 
selected centileτ in the interval [0, 1] were then constructed as )()(ˆ)(ˆ)|(ˆ 1 ttttQ −Φ+= σµτ [65]. 
Where )(1 t−Φ  denotes the inverse of the standard normal distribution function. These analyses 
were done using the gamlss package in R [70, 71]. Growth velocity is usually assessed in 
pediatric HIV using reference values from the Fels Institute cohort.[88-91] Estimates of the 3rd, 
50th, and 90th percentile of the six-month post-ART gains in weight and height were compared to 
that of a cohort of 818 non-HIV infected and otherwise healthy white American children from the 
Fels Institute. [56, 92] 
 
Association of lower percentiles with subsequent responses to ART  
Three outcomes were considered: time to death (survival), time to first virological suppression 
and time to treatment failure. For two children whose exact date of death was missing, the last 
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visit in the clinic was used as date of death. Virological suppression was defined as the first viral 
load measurement below 400 HIV RNA copies/ml. Treatment failure was defined as failure to 
achieve virological suppression after at least 1 year of ART, failure to achieve virological 
suppression prior to switch to second line regimen, or 2 viral load measurements above 1000 
RNA copies/ml after initial viral suppression.  
Kaplan Meier survival curves stratifying by the selected lower centiles (3rd, 10th, 25th, 33rd, 50th) 
of the 6 month weight, height, CD4, and CD4% gains and  log-rank test were used to assess the 
association with each of the outcomes.[63] For each of the 3 outcomes, five Cox proportional 
hazard models were fitted with each of the 5 selected centiles as predictors. Baseline WHO 
clinical stage (stage I/ II and III/ IV); level of immunosuppression (mild or not significant, 
advanced, and severe according to age specific CD4% and/or CD4 count values);[24] viral load 
(≥ or <5 log copies); tuberculosis treatment at ART initiation, age at ART initiation (< 1.5 years, 
1.5-3 years, 3-5 years, 5-8 years, and 8-15 years) and weight-for-age z score (WAZ) (≥ minus 
2SD, -2 to – 3SD, and <-3SD) [48, 49] were included in the initial model. Using a stepwise 
backward selection procedure and Wald test, all covariates that did not contribute significantly to 
the fit of each model were dropped. The Hazard ratio and 95% confidence interval (CI) from 
each of the final models were reported. All variables included in the model met the proportional 
hazard assumption formally evaluated using the Kolmogorov-type supremum test [75].  
Because attained weight- and height-for-age percentile curves are commonly available and 
familiar to health care workers (Road-to-Health), to evaluate whether attained growth can be 
used directly to monitor ART response, we also assessed the association between the lower 
percentile of the attained weight- and height-for-age at six months post-ART in our cohort and 
subsequent treatment outcomes. Analyses were done using SAS 9.1 (SAS Institute, Cary, NC). 
All tests were conducted using a 2-sided 0.05 significance level, without correction for multiple 
comparisons (or uncertainty due to model selection).   
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C. Results 
Description of the cohort  
As of March 31, 2008, 54 (3.7%) of the 1394 children included in the analysis had not been 
seen in the clinic for more than 6 months (Loss to follow-up), 18 (1.3%) were dead, and 66 
(4.7%) have been transferred out. Of the 1394 children, 699 (50.2%) were male, 872 (67.4%) in 
WHO clinical stage III&IV, 1120 (81.9%) were severely immuno-suppressed, 772 (58.3%) had 
viral load > 5 log RNA copies/ml, 378 (27.9%) had WAZ <-3SD, 512 (38.1%) had HAZ <-3SD, 
353 (25.3%) were on TB treatment, and 262 (18.8%) were 17 months or younger at the time of 
ART initiation (table 1).  
Of the 1394 children, 1249 (89.6%) had sufficient baseline and follow up data on weight, 1228 
(88.1%) on height, 1071 (76.8%) on CD4 count, and 1066 (76.5%) on CD4%. To avoid the 
influence of extreme values, 22 (1.8%) observations for weight, 17 (1.4%) for height, 16 (1.5%) 
for CD4 count, and 6 (0.6%) for CD4% were excluded. The distribution of baseline 
characteristics did not vary by availability of follow–up data.  
 
Six-month weight and height gain and their distribution compared to that of normal white 
American children of the Fels Institute cohort  
In the first 6 months post-ART, the median weight gain among boys was 2.73 kg among 
1 year-olds, decreased to 1.41 kg among 4 year-olds, after which it increased to 3.05 kg 
among 14 year-olds (table 2, figure 1). Similarly, median weight gain in girls was 2.63 kg 
among 1 year-olds, decreased to 1.37 kg among 5 year-olds, and rose to 3.16 kg 
among 15 year-olds. The median height gain decreased from 8.54 cm among 1 year-old 
to 1.79 cm among 12 year-old males, and from 8.58 cm among 1 year-old to a 2.18 cm 
among 12 year-old females (table 2, figure 2).  
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Compared to the gain observed among healthy US children (Fels Institute Cohort), the 
six-month weight gain whether at the lower or upper tails of the distribution was 
consistently higher in our cohort of HIV infected South African children initiating ART, 
and the height gain particularly in the lower tails of the distribution was substantially and 
consistently lower, with differences amounting to up to 2 cm for the 3rd percentile (table 
2). 
Six-month CD4 count and CD4% gain  
The CD4 count and CD4% improved substantially after ART initiation. While the gain in 
absolute CD4 count decreased with increasing age (from 672 cells among 1 year-olds 
to 310 cells among 6 year-olds and 154 cells among 15 year-olds), the gain in CD4% 
remained relatively stable across ages, ranging from 9.1% among 1 year-olds to 7.5% 
among 15 year-olds. (figure 3). Children below the 3rd percentile all had negative gains, 
and those below the 10th percentile barely maintained their baseline level of absolute 
CD4 or CD4% count (figure 3).     
Association between the 3rd, 10th, 25th, 33rd, and 50th percentile of six-month post-
ART weight, height, and CD4 gains and survival 
Of the 1394 children included in the analysis, 18 (1.3%) deaths occurred over the 
2792.2 years of follow-up, corresponding to a mortality rate of 6.4 (95%CI: 4.1, 10.2) 
deaths per 1000 child-years between 6 months and 47 months. Children in the lower 
percentile of weight, CD4 count, and CD4% gain at 6 months of ART had statistically 
higher crude hazard of death than those with greater gains (table 3). After adjustment 
for WHO clinical stage, WAZ, and TB treatment at ART initiation, the hazard ratios 
comparing children below the 33rd percentile of weight, CD4, and CD4% gains to those 
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above were 4.52 (95%CI: 1.47, 13.90) for weight, 3.03 (95%CI: 1.01, 9.11) for CD4 
count, and 2.60 (95%CI: 0.87, 7.74) for CD4%. Hazard ratios increased with lower 
percentiles. There was no association between six-month height gain and survival.  
Association between the 3rd, 10th, 25th, 33rd, and 50th percentile of six-month post-
ART weight, height, and CD4 gain and subsequent viral suppression 
Almost all children achieved virological suppression, with Kaplan Meier estimates of 
84.4% by 12 months and 96.4% by 24 months. Children in the lower percentile of 
weight, CD4 count, and CD4% gain at 6 months of ART were at lower hazard of 
virological suppression than those at higher percentiles (table 3). After adjustment for 
age (weight), or age and baseline WHO clinical stage (CD4 count and CD4%), the 
hazard ratios for viral suppression comparing children below the 33rd percentile to those 
above for weight, CD4, and CD4% gain at 6 months of ART were 0.80 (95%CI: 0.70, 
0.91), 0.79 (95%CI: 0.69, 0.92), and 0.73 (95%CI: 0.63, 0.84), respectively (table 3). 
The hazard ratios for viral suppression were smaller with lower percentiles. Height gain 
in the first 6 months of ART was not associated with virological suppression.  
Association between the 3rd, 10th, 25th, 33rd, and 50th percentile of six-month post-
ART weight, height, and CD4 gain and subsequent treatment failure 
The Kaplan Meier estimates of the proportion of children who failed treatment rose from 
0.1% by 12 months to 5.5% by 24 months and 20.1% at 36 months. Children in the 
lower percentiles of the distribution of weight, CD4 count, and CD4% gain at 6 months 
of ART were at increased hazard of treatment failure. After adjustment for WHO clinical 
stage and severity of immunosuppression at ART initiation, the hazard ratios for 
treatment failure comparing children with weight gain below the 33rd percentile to those 
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with gain above was 1.56 (95%CI: 1.07, 2.28) (table 3). For children falling below the 
33rd percentile of CD4 and CD4% gain, the hazard ratios were 1.46 (95%CI: 1.06, 2.30) 
and 2.43 (95%CI: 1.66, 3.57), respectively, after adjustment for WHO clinical stage and 
WAZ (table 3). As for survival, the strength of the association increased with lower 
percentiles.   
Association between the 3rd, 10th, 25th, 33rd, and 50th, percentile of attained weight 
and height for age (Road-to-Health chart) at six months post-ART and subsequent 
treatment outcomes 
Six-month after ART, the median weight-for-age and height-for-age attained in our 
cohort was below the 8th (WAZ = -1.41) percentile for weight and below the 1st (HAZ = -
2.37) percentile for height on the Road-to-Health chart. Children below the third 
percentile for weight tended to be at higher risk for death (aHR 4.63, 95% CI 0.78, 
27.42), but there was no correlation between weight or height for age at 6 months of 
ART and virological suppression or treatment failure (table 4).   
D. Discussion 
It is well established that poor nutritional status and stunting at time of ART initiation are 
correlated with poor prognosis of HIV infection in children.[50, 55]  Monitoring height 
and weight is routinely performed in the follow up of children, but there are no reference 
values for weight or height gain among children receiving ART.[24] We constructed 
reference curves for monitoring 6 month gains in weight, height, CD4 count, and CD4% 
in children initiating ART, and demonstrated that lower percentiles of CD4% gains, 
weight and CD4 count, but not height, were associated with treatment outcomes, with 
increasing strength of association with decreasing percentiles.  
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In our cohort of South African children, six-month weight gain was consistently and 
substantially higher than that observed in the Fels cohort of white American children 
enrolled prenatally and followed-up between 1929 to 1978, while six-month height gain 
was consistently lower across all ages and gender.[56, 92] Similar differences  have 
been observed with South African children born between April  and June, 1990, (when 
the HIV prevalence among pregnant women was 0.7%),[93] suggesting that the 
differences between our cohort of HIV infected children and healthy US children may 
only in part be due to the presence of HIV infection.  
The Fels reference values have been used in several pediatric antiretroviral drug trials 
in the US. [88-91] Our results demonstrate that using the Fels cohort as a reference for 
HIV infected children in South Africa, may result in an important underestimation of the 
number of children at risk of poor ART outcomes. For example, a boy who initiates ART 
at age 18 months and gains 1.5 kg in the first 6 months has a weight gain of the 90th 
percentile (+1SD) on the Fels cohort growth velocity curves, but scores below the 10th 
percentile (-1SD) on our newly developed reference curves of weight gain for HIV 
infected children on ART. A close follow up of this child would be warranted as his 
weight gain predicts a 6.7-fold hazard of death,  1.8 fold hazard of virologic failure and 
reduced likelihood (adjusted HR 0.8) of virological suppression, compared to children 
with gender- and age-specific weight gain above the 10th percentile.  
In contrast to six month weight gain plotted on our newly developed reference charts for 
HIV- infected children, weight at six months of ART plotted on standard weight-for-age 
charts, did not appear appropriate for the purpose of monitoring ART response in our 
cohort. In our cohort, though as expected children with weight-for-age or height-for-age 
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below the 3rd percentile were at increased hazard for subsequent mortality, there was 
no correlation with subsequent virological suppression or treatment failure.   
CD4% gained in the first 6 months of ART showed the strongest association with poor 
ART outcomes. Monitoring gains in CD4% are particularly attractive as the CD4% gain 
was relatively stable across ages. In our cohort, children whose CD4% gain was less 
than 6 % after 6 months of ART fell below the 33rd percentile of CD4% gain and had a 
2.6-folds increased hazard of death, 2.4-fold greater hazard of treatment failure and 
were less likely (adjusted HR 0.7) to achieve viral suppression compared to children 
who gained 6% or more in CD4%. However, as with viral load, access to CD4% 
measurement is not widespread in resource poor settings, limiting its usefulness in 
monitoring ART response.  
Our analysis has many strengths including a large sample size and a long follow-up 
(median follow-up time on ART 25 months), and the use of three different outcomes 
limiting the impact of potential errors that might result from measurement of each.  Our 
analysis also has a number of limitations. First, we only focus on one interval: the first 6-
month of ART, chosen to match the recommended time for viral load or CD4 
measurement [57] and in accordance with previous studies [50, 55]. Second, most 
children were referred after hospitalization, with few children being referred from primary 
health care clinics, thus selecting for children that may have been sicker at ART 
initiation and have greater gains in weight, height, and CD4 cell count if they survive the 
early weeks of treatment.[37]  Although children in our cohort do not appear to differ 
substantially at ART initiation from children in other cohorts in the region [38, 61], 
reference curves constructed from a more representative population are needed.  Third, 
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despite ART treatment some children had negative weight, height, CD4, and CD4% 
gains at 6 months. Although negative gains in CD4 cell count and weight can occur, 
negative height or length gains are likely due to measurement error occurring under 
routine conditions in a busy clinic. It has been shown that because of measurement 
errors, a single height velocity measurement even at 12 months lacks the precision to 
provide a reliable index of current growth, particularly in short children.[94] Third, some 
important confounders like adherence were not measured and could not be adjusted 
for.  
Conclusion:  We demonstrated that though weight gain is an excellent tool for 
monitoring the early response to ART, growth references from non HIV-infected children 
do not properly discriminate HIV-infected children with inappropriate growth response to 
ART. Our results also suggest that even with the reference distributions we constructed, 
the usual -2SD (3rd percentile) cut-off for growth failure definition misses a lot of children 
that are at high risk of failing ART and that substantially higher cut-offs should be 
considered. Gain in CD4% in the first six month of ART was the best predictor of poor 
subsequent ART outcomes. But in areas with limited access to viral load or CD4 
measurement, weight gain post-ART using our newly developed reference distributions 
for HIV-infected children on ART is a good alternative.  
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Table V-1. Characteristics at ART initiation of 1394 children included in the analysis of 
six-month weight, height, CD4 cell gain* 
Characteristic at ART initiation Frequency Percentage 
Sex   
Male 699 50.18 
Female 694 49.82 
WHO Clinical stage   
 1 or 2 422 32.61 
 3 0r 4 872 67.39 
Severity of immunosuppression (WHO)   
Mild or not significant   158 11.55 
Advanced  90 6.58 
 Severe   1120 81.87 
Viral load   
>=100 000 copies/ml 772 58.31 
 <100000 copies/ml 552 41.69 
Weight-for-age z score†   
>=-2SD 668 49.34 
-2 to -3SD 308 22.75 
< -3SD 378 27.92 
Height-for-age z score†   
>=-2SD 430 32.02 
-2 to -3SD 401 29.86 
< -3SD 512 38.12 
TB treatment at ART initiation  
No 1041 74.68 
Yes 353 25.32 
Age at ART initiation   
< 1.5 years 262 18.79 
1.5 – 2.9 years 239 17.14 
3.0 – 4.9 years 254 18.22 
5.0 – 7.9 years 349 25.04 
8.0 – 15.0 years 290 20.8 
Time on ART in months median (IQR)  25.2 
(17.9 to 
33.5)‡ 
*Children were included if they had at least 6 months of follow-up on ART and at least a pre-ART and a 6-month 
measurement needed to estimate the six-month gain. Those children were part of a cohort of HIV-infected children 
who were initiated on ART at HSCC between April, 2004 and March, 2008. IQR = interquartile range.  
†Gender specific weight- and height- for-age z score were obtained by plotting the weight measurements at baseline 
against the Word health organization (WHO) weight- and height-for-age charts for children <= 5years and against the 
Center for Disease and Control prevention (CDC) for children older than 5 years. ‡ Minimum = 6 months, Maximum = 
47 months
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Table V-2. Six-month weight, height gains in a cohort of 1394 HIV-infected children who were initiated on ART at HSCC (Soweto) between April, 
2004 and March, 2008 compared to six-month gains among white non HIV-infected North American children of the Fels Institute cohort† 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Serial data from 818 normal white American children from the Fels Longitudinal Study [56]. HSCC: Harriet Shezi Children’s Clinic 
  Age (in years) 
Percentile 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
6-month weight gain (Kg/6 months) 
Male 
3rd Fels 1.20 0.38 0.28 0.24 0.14 0.07 0.21 0.20 -0.46 0.01 0.15 -0.36 0.10 -0.61 -2.99 
     HSCC 1.16 0.62 0.26 0.08 0.08 0.12 0.09 0.09 0.14 0.20 0.27 0.37 0.55 0.77 - 
50th Fels 2.20 1.13 0.97 0.95 1.06 1.18 1.26 1.52 1.56 1.70 1.73 2.00 2.81 3.33 3.24 
       HSCC  2.83 2.08 1.59 1.38 1.45 1.58 1.61 1.68 1.83 2.02 2.23 2.51 2.94 3.47 - 
90th Fels  3.13 1.65 1.52 1.46 1.76 2.01 2.25 2.54 2.95 3.14 3.51 4.24 5.29 5.71 5.73 
       HSCC  4.04 3.16 2.59 2.38 2.53 2.77 2.88 3.06 3.38 3.75 4.18 4.74 5.54 6.59 - 
Female 
3rd Fels 1.30 0.41 0.24 0.11 0.05 0.05 0.16 -0.08 0.14 -0.10 -0.50 -0.41 -1.53 -2.15 -3.61 
     HSCC 1.13 0.58 0.29 0.15 0.04 0.00 0.02 0.04 0.02 0.02 0.04 0.05 0.02 -0.09 -0.24 
50th Fels 2.19 1.21 1.02 0.98 1.03 1.12 1.18 1.36 1.47 1.57 2.01 2.74 2.15 1.83 1.00 
       HSCC  2.63 1.91 1.56 1.44 1.37 1.40 1.57 1.76 1.90 2.10 2.40 2.74 3.04 3.24 3.16 
90th Fels  3.02 1.80 1.59 1.54 1.73 1.97 2.27 2.73 2.97 3.48 3.94 5.11 4.15 4.13 3.45 
       HSCC  3.95 3.08 2.69 2.60 2.55 2.66 2.97 3.30 3.59 3.96 4.49 5.11 5.67 6.10 6.40 
6-month height gain (cm/6 months) 
Male 
3rd Fels 5.89 3.26 2.33 2.14 2.08 1.99 1.99 1.69 1.77 1.80 1.49 1.49 1.61 1.53 0.65 
     HSCC 3.40 1.73 1.20 1.16 1.02 0.75 0.50 0.38 0.23 0.03 -0.12 -0.25 -0.17 -0.07 - 
50th Fels 8.51 5.40 4.05 3.59 3.53 3.35 3.19 3.02 2.84 2.70 2.52 2.73 3.29 4.01 3.19 
       HSCC  8.54 5.52 4.55 4.51 4.26 3.74 3.25 3.05 2.76 2.35 2.07 1.79 1.98 2.23 - 
90th Fels  10.14 6.85 5.38 4.41 4.41 4.10 3.93 3.75 3.52 3.44 3.70 4.07 5.22 5.21 4.66 
       HSCC  11.64 7.71 6.45 6.38 6.06 5.43 4.83 4.61 4.26 3.75 3.43 3.08 3.39 3.76 - 
Female 
3rd Fels 5.94 3.72 2.54 2.50 2.20 2.07 1.96 1.62 1.81 1.63 1.67 1.67 0.36 -0.28 -0.62 
     HSCC 2.01 1.81 1.17 0.86 0.67 0.43 0.13 0.00 -0.08 -0.20 -0.44 -0.41 -0.35 -0.19 - 
50th Fels 8.49 5.59 4.13 3.65 3.52 3.30 3.08 3.01 2.84 2.91 3.06 3.32 2.76 1.33 0.68 
       HSCC  8.58 6.21 4.97 4.41 4.10 3.65 3.05 2.84 2.74 2.54 2.29 2.18 2.45 2.98 - 
90th Fels  10.34 7.09 5.25 4.49 4.36 4.10 3.81 3.85 3.53 3.83 4.33 4.52 4.09 3.11 1.75 
       HSCC  11.64 8.63 7.07 6.39 6.03 5.48 4.72 4.49 4.39 4.16 3.85 3.75 4.15 4.94 - 
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Table V-3.  Association between lower percentile of weight, height, absolute CD4 count, and CD4% gain at 6 months of 
ART and time to death, virological suppression, and treatment failure in a cohort of 1394 HIV-infected children from 
Soweto, South Africa  
 Time to Death after 6 months   Time to Viral suppression**   Time to Treatment Failure£ 
 HR (95 Confidence Interval)   HR (95 Confidence Interval)   HR (95 Confidence Interval) 
  crude Adjusted*   crude adjusted†  crude adjusted‡ 
 
Weight 
3rd   8.32 (2.32, 29.84) 6.90 (1.81, 26.20)   0.71 (0.52, 0.98) 0.69 (0.48, 0.98)  1.83 (0.75, 4.51) 2.56 (1.04, 6.32) 
10th   6.04 (2.02, 18.04) 7.12 (2.29, 22.11)  0.83 (0.68, 1.02) 0.79 (0.63, 0.98)  1.57 (0.86, 2.85) 1.84 (1.00, 3.38) 
25th  3.60 (1.26, 10.27) 5.29 (1.76, 15.88)  0.86 (0.75, 0.99) 0.82 (0.71, 0.96)  1.21 (0.80, 1.83) 1.31 (0.86, 2.01) 
33rd  2.85 (0.99, 8.21) 4.52 (1.47, 13.90)  0.83 (0.73, 0.94) 0.79 (0.70, 0.91)  1.44 (1.00, 2.07) 1.56 (1.07, 2.28) 
50th  2.38 (0.75, 7.59) 2.89 (0.87, 9.56)   0.87 (0.78, 0.98) 0.84 (0.74, 0.95)  1.30 (0.89, 1.84) 1.47 (1.01, 2.16) 
  
Height 
3rd   1.62 (0.21, 12.38) 1.95 (0.25, 15.20)   1.00 (0.77, 1.30) 0.97 (0.74, 1.29)  0.15 (0.02, 1.06) 0.22 (0.03, 1.55) 
10th   2.76 (0.87, 8.81) 2.26 (0.68, 7.45)  1.08 (0.91, 1.28) 1.02 (0.89, 1.17)  0.81 (0.49, 1.36) 0.84 (0.49, 1.44) 
25th  1.36 (0.46, 4.07) 1.35 (0.44, 4.14)  1.08 (0.95, 1.23) 1.03 (0.91, 1.17)  0.74 (0.49, 1.11) 0.73 (0.48, 1.13) 
33rd  1.25 (0.43, 3.61) 1.30 (0.44, 3.87)  1.08 (0.96, 1.22) 1.03 (0.91, 1.17)  0.77 (0.53, 1.12) 0.76 (0.51, 1.13) 
50th  1.72 (0.58, 5.12) 2.15 (0.65, 7.08)   1.05 (0.93, 1.18) 0.99 (0.87, 1.12)  0.75 (0.52, 1.07) 0.75 (0.51, 1.10) 
  
CD4 count 
3rd   2.70 (0.35, 2.69) 5.56 (0.69, 44.83)   0.84 (0.59, 1.20) 0.86 (0.58,  1.28)  0.48 (0.07, 3.44) - 
10th   3.74 (1.04, 13.42) 5.40 (1.46, 20.00)  0.57 (0.45, 0.72) 0.54 (0.42, 0.69)  3.37 (2.01, 5.64) 3.42 (1.96, 5.99) 
33rd  2.95 (1.02, 8.49) 3.03 (1.01,  9.11)  0.80 (0.70, 0.91) 0.79 (0.69, 0.92)  1.43 (0.99, 2.05) 1.56 (1.06, 2.30) 
50th  1.59 (0.53, 4.73) 1.51 (0.49, 4.66)   0.92 (0.81, 1.04) 0.90 (0.79, 1.03)  1.21 (0.84, 1.75) 1.23 (0.82, 1.83) 
  
CD4 count Percentage 
3rd   11.01 (3.07, 39.50) 19.43 (4.88, 77.38)   0.52 (0.35, 0.77) 0.50 (0.32, 0.78)   7.00 (3.51, 13.96) 8.75 (3.93, 19.48) 
10th   8.31 (2.88, 23.97) 9.11 (3.03, 27.34)  0.65 (0.52, 0.81) 0.59 (0.47, 0.76)  4.28 (2.70, 6.80) 4.40 (2.68, 7.23) 
25th  3.48 (1.22, 9.91) 4.31 (1.44, 12.88)  0.75 (0.65, 0.87) 0.73 (0.62, 0.85)  2.75 (1.92, 3.95) 2.73 (1.85, 4.04) 
33rd  2.28 (0.80, 6.50) 2.60 (0.87, 7.74)  0.75 (0.66, 0.86) 0.73 (0.63, 0.84)  2.39 (1.67, 3.41) 2.43 (1.66, 3.57) 
50th  1.20 (0.42, 3.45) 1.11 (0.37, 3.31)   0.82 (0.73, 0.93) 0.81 (0.71, 0.92)   1.57 (1.07, 2.28) 1.57 (1.05, 2.34) 
*Adjusted for Baseline WHO clinical stage, Baseline weight-for-age z score (WAZ), and TB treatment at ART initiation. †Adjusted for age for weight and height, baseline WHO clinical stage and age 
for CD4 count and CD4 percentage. ‡Adjusted for baseline WHO clinical stage and severity of immunosuppression for weight and height, baseline WHO clinical stage and WAZ for CD4 cell count and 
CD4%. **Viral load < 400 HIV RNA copies/ml, £2 viral load > 1000 after initial suppression or never suppress or > 1 year follow without viral suppression and regimen change
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Table V-4.  Association between lower percentile of attained weight- and height-for-age at 6 months of ART and time to 
death, virological suppression, and treatment failure in a cohort of 1394 HIV-infected children from Soweto, South Africa  
  Time to Death after 6 months   Time to Viral suppression**   Time to Treatment Failure£ 
 HR (95 Confidence Interval)   HR (95 Confidence Interval)  HR (95 Confidence Interval) 
  crude Adjusted*   crude adjusted†   crude adjusted‡ 
  
Weight 
3rd   6.51 (1.82, 23.34) 4.63 (0.78, 27.42)   0.98 (0.87, 1.11) 0.98 (0.86, 1.11)  0.80 (0.55, 1.16) 0.74 (0.50, 1.10) 
10th   2.87 (0.80, 10.28) 1.31 (0.25, 6.88)  0.99 (0.88, 1.11) 0.98 (0.86, 1.11)  1.02 (0.71, 1.47) 1.01 (0.69, 1.49) 
25th  1.90 (0.43, 8.48) 0.81 (0.14, 4.61)  1.00 (0.87, 1.14) 0.97 (0.85, 1.12)  1.07 (0.70, 1.66) 1.04 (0.65, 1.65) 
33rd  1.39 (0.31, 6.22) 0.65 (0.12, 3.58)  0.97 (0.84, 1.12) 0.93 (0.80, 1.09)  1.45 (0.84, 2.45) 1.37 (0.78, 2.41) 
50th  - -   0.94 (0.78, 1.14) 0.90 (0.73, 1.10)   0.92 (0.48, 1.75) 0.80 (0.40, 1.59) 
  
Height 
3rd   2.93 (0.66, 13.08) 1.37 (0.24, 7.70)   0.95 (0.84, 1.07) 0.95 (0.84, 1.08)  1.00 (0.67, 1.49) 1.03 (0.67, 1.57) 
10th   2.94 (0.39, 22.45) 1.45 (0.16, 13.20)  0.93 (0.81, 1.08) 0.93 (0.80, 1.08)  0.95 (0.58, 1.55) 1.02 (0.61, 1.72) 
25th  0.96 (0.13, 7.37) 0.31 (0.03, 3.15)  0.81 (0.65, 1.01) 0.85 (0.67, 1.07)  1.30 (0.53, 3.19) 1.22 (0.50, 3.00) 
33rd  0.61 (0.08, 4.65) 0.20 (0.02, 2.08)  0.82 (0.63, 1.08) 0.82 (0.61, 1.08)  0.90 (0.33, 2.45) 0.85 (0.31, 2.33) 
50th  0.26 (0.03, 1.99) 0.08 (0,01, 0.84)   1.00 (0.68, 1.46) 0.98 (0.66, 1.47)   0.72 (1.18, 2.93) 0.74 (0.18, 3.01) 
*Adjusted for Baseline WHO clinical stage, Baseline weight-for-age z score (WAZ), and TB treatment at ART initiation. †Adjusted for age . ‡Adjusted for baseline WHO clinical stage and severity of 
immunosuppression. **Viral load < 400 HIV RNA copies/ml, £2 viral load > 1000 after initial suppression or never suppress or > 1 year follow without viral suppression and regimen 
change
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Figure V-1.  Gender- and age-specific six-month weight gain reference curves in children who were initiated on ART at 
HSCC (Soweto) between April, 2004 and March, 2008  
  
Curves were obtained using Box Cox power exponential distribution (BCPE) LMS and GAMLSS. HSCC: Harriet Shezi Children’s Clinic  
Model for male: BCPE (age, df(µ) = 4, df(σ) = 0.5,  df(υ) =0, df(τ)=1). Model for female: BCPE (age, df(µ) = 5.3, df(σ) = 0, df(υ) =0, df(τ)=0)
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Figure V-2.  Gender- and age-specific six-month height gain reference curves among children who were initiated on ART 
at HSCC (Soweto) between April, 2004 and March, 2008  
  
The curves were obtained using Box Cox power exponential distribution (BCPE) LMS and GAMLSS. HSCC: Harriet Shezi Children’s Clinic 
Model for male: BCPE (age, df(µ) =9.1 , df(σ) =0 , df(υ) =0, df(τ)=2). Model for female: BCPE (age, df(µ) =7, df(σ) =0, df(υ) =0, df(τ)=0). 
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Figure V-3.  Age-specific six-month CD4 count and CD4% gain reference curves among children who were initiated on 
ART at HSCC (Soweto) between April, 2004 and March, 2008 
  
 
The curves were obtained using Box Cox power exponential distribution (BCPE) LMS and GAMLSS. HSCC: Harriet Shezi Children’s Clinic 
Model for CD4 count: BCPE (age, df(µ) = 3, df(σ) = 0, df(υ) =0, df(τ)=1). Model for CD4%: BCPE (age, df(µ) = 0, df(σ) = 5, df(υ) =0, df(τ)=0). 
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VI. EFFECT OF DELAYING ANTIRETROVIRAL THERAPY INITIATION IN HIV/TB CO-
INFECTED CHILDREN ON SURVIVAL AND VIROLOGICAL RESPONSE  
A. INTRODUCTION 
Worldwide, it is estimated that about 1500 new pediatric HIV infections occur daily and 
more than 90% of those new infections happen in sub-Saharan Africa [1, 2]. Children 
who are infected early in life progress more rapidly to acquired immuno-deficiency 
syndrome (AIDS) and death. Primary and reactivated tuberculosis (TB) is a major cause 
of morbidity and mortality among HIV-infected children in Africa [15]. Following TB 
infection, children (particularly young infants), have a higher risk of progression to 
disease (extra-pulmonary and pulmonary) and death irrespective of their HIV status 
[17]. However, HIV is a major risk factor for childhood TB [18]. The burden of TB in HIV-
infected children is not well known because of the difficulties in diagnosing TB in these 
children [95],  Reported prevalences of HIV among TB-infected children range from less 
than 5% in industrialized settings to over 50% in some high-burden African settings [8-
10]. In HIV/TB co-infected children, diminished cell-mediated immunity increases the 
risk for disseminated TB disease, especially in advanced stages of HIV infection, 
resulting in high mortality [19, 20]. Restoration of cellular immunity with antiretroviral 
therapy (ART) reduces the susceptibility to tuberculosis [21].  
Because of the high risk of disease progression, the World Health Organization (WHO) 
recommends initiation of TB treatment as soon as the diagnosis of TB is suspected in 
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an HIV-infected child. The management of HIV-infected children with TB is however 
complicated. Rifampicin, the backbone of any TB treatment regimen reduces the serum 
concentrations of most protease inhibitors by about 80% or more, and that of non-
nuclease reverse transcriptase inhibitors by 20% to 60% [24]. In addition, TB and 
antiretroviral drugs have overlapping toxicities. To avoid drug interactions and to 
differentiate side effects for TB and antiretroviral drugs, WHO advises that initiation of 
ART be delayed for at least 2-8 weeks after TB treatment initiation [24, 30]. In South 
Africa (SA), the guidelines  recommend  completion of TB therapy before starting ART 
in children with clinical stage 3, CD4 percentage (CD4%) < 25% in children under 18 
months of CD4% < 20% in older children or to delay ART for 4 to 8 weeks ,in children 
with severe immunosuppression.[96]. The potential effects of these delays on survival 
or virological response to ART are unknown. 
In this study we aimed to estimate the effect of delaying ART initiation for at least 15, 
30, or 60 days in HIV/TB co-infected children on virological suppression and survival. 
We hypothesized that children in whom ART is delayed will be at higher hazard of death 
but will be more likely to achieve viral suppression once they are initiated on ART.  
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B. METHODS 
Data 
We used information from a cohort of HIV-infected children, who sought care at the 
Harriet Shezi Children’s Clinic, an outpatient pediatric HIV clinic at Chris Hanni 
Baragwanath Hospital in Soweto, SA, during the first four years (April 2004 to March 
2008) of the government sponsored ART program [97]. TB was routinely diagnosed on 
clinical grounds including severe failure to thrive, prolonged (more than two weeks) 
cough, suspicious chest radiograph with or without a positive contact history. 
Bacteriological confirmation of clinical suspicion was attempted in older children who 
can produce a sputum sample. Children are treated according to national guidelines 
with a combination of rifampicin, isoniazid, and pyrazinamide for the initial 2 months 
followed by rifampicin + isoniazid for the remaining 4 months [59].  
According to the SA National Guidelines, all children diagnosed with TB are eligible for 
ART. The first line ART regimen for children receiving TB treatment consists of 
stavudine, lamivudine, and ritonavir-boosted lopinavir (LPV/r) for children 3 years or 
younger; or stavudine, lamivudine and efavirenz for those over 3 years and over 10kg of 
weight.  
Children initiated on ART were clinically reevaluated at 1 month, at 3 months, and every 
3 months thereafter or as needed clinically. At each scheduled visit, children were 
assessed clinically and weight and height (children 2 years or older) or length (children 
< 2years) were recorded. Laboratory investigations (viral load, and CD4 cell count) were 
done at baseline and every 6 months or whenever indicated. Clinical and laboratory 
information were entered in an electronic database.  
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Children where included in this analysis if: their first visit in the clinic occurred between 
April 1st, 2004 and March 31st, 2008, they were initiated on TB treatment prior to ART 
initiation, and were 15 years or younger at the time of TB treatment initiation. Children 
who were already on TB treatment at first visit in the clinic were excluded. For analysis 
of time to viral suppression, eligible children had to also have at least one post-ART 
viral load measurement.  
Two main outcomes were considered: (1) Time to death (survival) defined as time from 
TB treatment initiation to death. For 6 children whose exact dates of death were 
unknown, the last clinic visit date was used. (2) Time to viral suppression defined as 
time from ART initiation to the date of first viral load measure below 400 HIV RNA 
copies/ml.  
Time from TB treatment initiation to ART initiation (Timing of ART) was categorized at 3 
points: 15, 30, and 60 days for each of the 3 main exposures. The 15, 30, and 60 days 
cut-offs were chosen to approximate the minimum 2 to 8 weeks delay between TB 
treatment and ART initiation recommended by the WHO [24].  
Additional covariables considered were: level of immunosuppression (CD4%  below 
25% for children younger than 1, or below 20% for children 1 to 2 years, or below 15% 
for children 3 to 15 years) [24], log viral load dichotomized at about the median (5 log10 
copies/ml), age at TB initiation categorized to capture the average change in the rate of 
death in less than 18 months, 18-35 months, 36-59 months, 60 months or older, and  
weight-for-age Z score (WAZ) categorized in -2SD or greater, -2SD to -3SD, and less 
than - 3SD [49, 62].  
Statistical analysis 
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Baseline characteristics (at time of TB treatment initiation), were compared using Wilcoxon 
Rank Sum test for continuous variables and Pearson Chi square for  categorical variables.  
For the analysis of mortality, though per guidelines all children with TB were eligible for ART, the 
decision whether to initiate or delay ART for a given child was made at each visit based on 
clinical and immunological characteristics of the child at the given visit. Thus, children with more 
advanced disease and at higher risk of death were likely to be initiated on ART earlier than 
those who appeared relatively healthier. In addition, children in whom ART was delayed and 
whose follow-up time in the clinic was less than the cut-off point considered for each exposure 
could not be classified. To adjust for time-dependant confounding and account for the lead time,  
inverse-probability-of-treatment  weighting (IPTW) of marginal structural models was used [76, 
78]. IPTW estimator is an extension of the Horvitz & Thompson estimator for population means 
and totals in survey statistics [79]. But contrary to surveys where the probability of selection and 
therefore weights are known and fixed, for the IPTW, and in this analysis, the probability of 
staying in the study until a given time and initiating ART at that time has to be estimated from 
the observed sample  and can be highly variable [78]. To limit the variability of estimated 
weights, stabilized weights are recommended [78]. To estimate the stabilized weights, time from 
TB treatment initiation to ART was treated as failure time and categorized as: less than 15 days, 
15 to 30 days, 30 to 60 days, 2 to 3 months, 3-4, 4-5, 5-6, and 6 months or greater. These cut-
offs were selected to reflect the categorization of the exposure (delay between initiation of TB 
treatment and ART) and to ensure that there were enough observations in each group to fit the 
models. For the numerator of stabilized weights, 2 pooled logistic models for the probabilities of 
initiating ART or remaining in care (censoring weights) in each time interval were specified with 
level of immunosuppression, log viral load, WAZ, and age at TB treatment initiation as fixed 
covariates. For the denominator, the same pooled logistic models above were specified with 
level of immunosuppression, log viral load, and WAZ as time-varying covariates in addition to 
age at TB initiation treated as fixed. Apart from the initial visit, if a patient had more than 1 
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measurement for a time-varying covariable in a time interval, only the last measurement was 
considered. The product of the stabilized weights for censoring and stabilized weights for ART 
initiation was used for the final weights. Assuming  no misspecification of the models for weight 
estimation  and provided that data are available on all time-varying and baseline joint predictors 
of ART initiation and mortality, the IPTW is a valid method to account for such confounding [76-
78]. A necessary condition for correct model specification is that the stabilized weights have a 
mean of one [83]. The mean of the final weights was 1.00 and its values ranged from 0.44 to 
15.76. Using the estimated weights, weighted Cox proportional models were fitted for mortality 
and each of the 3 exposures.   
Children had to be on ART to be at risk of viral suppression. Hence, the only potential source of 
confounding that had to be adjusted for in the estimation of the effect of timing of ART initiation 
on viral suppression were the fixed baseline characteristics. Cox proportional models were used 
to obtain the crude and adjusted effect of the timing of ART initiation on virological suppression. 
All covariates included in the models were formerly assessed for the proportional hazard 
assumption using the Kolmogorov-type supremum test [75].  
To assess if the effects of delaying ART on mortality or viral suppression vary by the 
level of immunosupression at baseline, each analysis was repeated in each stratum of 
level of immunosuppression when there were sufficient data. All analyses were 
conducted using SAS 9.1 (SAS Institute, Cary, NC) and all tests were conducted using 
a 2-sided 0.05 significance level, without correction for multiple comparisons. All 
confidence intervals (CI) were estimated using robust variances [98]. 
 62 
 
C. RESULTS 
Between April 2004 and March 2008, 3187 HIV-infected children received care in the 
clinic for the first time, 1341 of whom were on TB treatment at some point of follow-up at 
the clinic. In 909 children, TB treatment was initiated after their initial visit in the clinic. 
Of those 909, 8 were older than 15 years and 328 were already on ART at the time of 
TB treatment. The remaining 573 children were  included in this analysis, of whom 461 
(80.5%) were subsequently initiated on ART at a median time of 17 [Interquartile range 
(IQR): 0 to 49] days after TB treatment initiation. As of March 31st, 2008, 75 (13.0%) of 
those children had not been seen in the clinic for at least 6 months and their 
whereabouts were unknown (loss to follow-up): 38 of them prior to ART initiation and 37 
while on ART. Children lost to follow-up did not differ from those still in care by any of 
the baseline characteristics or timing of ART initiation.  
The 573 children were followed for a median time of 9.6 (IQR: 1.9 to 23.1) months. 
Follow-up time was administratively censored at 36 months. At baseline, the median 
CD4% was 11.9% (IQR: 6.6% to 18.3%), 75.2% of children were severely 
immunosuppressed, the median log viral load was 5.2 (IQR: 4.5 to 5.9) log copies/ml,  
58.6% of children had viral load greater than 5 log copies/ml, the median WAZ was -2.3 
(IQR: - 3.6 to -1.3) with 34.7% of children severely underweight-for-age (WAZ <-3SD), 
the median age was 3.5 (IQR: 1.4 to 6.8) years and 26.5% of children were younger 
than 1.5 years (table 1). Children who were initiated on ART earlier (within one month of 
start TB treatment) had lower CD4 count, lower WAZ, and higher viral load in general 
than those in whom ART was delayed (table 1).  
Mortality 
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Of the 573 children eligible for the analysis, 37 died during follow-up; 30 among 461 
children initiated on ART: 22, 25, 26 respectively among the 226, 288, 378 initiated on 
ART within 0 to 15, 0 to 30, 0 to 60 days of TB treatment. Children who died were more 
likely at baseline to be younger (median age 1.4 vs 3.7 years, p < 0.01), to be severely 
underweight for age (median WAZ – 3.8 vs -2.2, p < 0.01), and to have higher viral load 
(median 5.9 vs 5.2, p <0.01). The hazard ratio for death comparing children with severe 
immunosuppression to those without at baseline was 2.38 (95%CI: 0.85, 6.68) (table 2).     
Delaying ART for ≥15 or 30 days had no effect on mortality (adjusted hazard ratio 
(aHR): 0.90 , 95%CI: 0.30, 2.75 and 1.05, 95%CI: 0.29, 3.75, respectively). However, 
delaying ART initiation for ≥60 days after TB treatment initiation tended towards higher 
hazards of death, with aHR of 2.18 (95%CI: 0.64, 7.24). All hazard ratios account for the 
time-varying level of immunosuppression, log viral load, WAZ, and censoring prior to 
ART, and time fixed age at TB treatment initiation (table 3).  
Full stratification of the analysis of mortality by level of immunosuppression was not 
possible because only 4 deaths occurred among the 125 children not severely 
immunosuppression at baseline (1 immediately after TB treatment initiation and before 
ART and 3 others after ART initiation). Restriction of the analysis to children with severe 
immunosuppression resulted in stronger and more précised effects. The aHRs for 
delaying ART for ≥15, ≥30, or ≥60 days were: 1.14 (95%CI: 0.65, 2.01), 1.36 (95%CI: 
0.77, 2.41), and 3.40 (95%CI: 1.92, 6.02). 
Virological suppression 
Of the 461 children initiated on ART, 324 (70.3%) had at least one viral load 
measurement after ART initiation, of whom 291 (89.8%) ever achieved viral load below 
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400 copies/ml. Children who achieved virologic suppression were more likely at the time 
of TB treatment initiation to be older (median age 4.0 vs 1.6 years, p < 0.01), to have 
higher weight-for-age (median WAZ – 2.2 vs -3.1, p < 0.02), and to have lower viral load 
(median 5.2 vs 5.8, p = 0.01). 
Delaying ART for ≥15 or 30 days had no effect on viral suppression (aHRs = 0.98, 
95%CI: 0.76, 1.26, and 0.95, 95%CI: 0.73, 1.23, respectively), but delaying for 60 days 
or longer after TB treatment initiation tended towards lower hazards of achieving 
virological suppression: 0.84 (95%CI: 0.54, 1.10); i.e. children who initiated ART more 
than 60 days after start TB treatment were 16 % less likely to achieve viral suppression 
compared to those who started earlier . All HR adjusted for level of immunosuppression, 
log viral load, WAZ, and age at TB treatment initiation (table 3).  
Full stratification of the analysis of viral suppression by level of immunosuppression was 
also not possible because of the 324 children included in the analysis for viral 
suppression, only 63 were not severely immunosuppressed at baseline and just 6 of 
them had not yet achieved virologival suppression at the time of this analysis (all but 
one with 6 months or less of follow-up on ART). Restricting the analysis to only severely 
immunosuppressed children did not change the results substantially. The aHRs were 
0.96 (95%CI: 0.73, 1.26), 0.91 (95%CI: 0.67, 1.24), and 0.77 (95%CI: 0.50, 1.18).   
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D. Discussion 
We sought to estimate the effect of delaying ART initiation in children receiving TB 
treatment on mortality and virologic response to ART. Our results showed that, a short 
delay (less than 30 days) between TB treatment and ART initiation had no effect on 
mortality and viral response to ART. The effect of delaying ART for 60 days or more 
tended towards higher higher hazards of death and lower hazards of viral suppression, 
but results were imprecise and not statistically significant. However, when the analysis 
was restricted to children severely immunosuppressed at TB treatment initiation, 
Delaying ART for 60 days or more, more than triple the hazard of death and was 
statistically significant (aHR 3.40, 95CI: 1.92, 6.02). ART is well known to improve 
survival in HIV infected children [37, 57, 61, 99] and early initiation of ART even in 
asymptomatic infants has been shown to substantially improve survival [100].  
The principal justification for delaying ART in HIV/TB co-infected children is to allow 
differentiation between side effects from ART and TB drugs, and to improve the viral 
response by avoiding drug interactions [30]. The observation that children for whom 
ART was delayed for 60 days or more, appeared actually to be less likely to achieve 
viral suppression suggests that the current recommendation of delaying ART in children 
with TB has no benefit on virological response to ART.  
Our analysis had several strengths. First, we used data from one of the largest pediatric 
HIV clinics in sub-Saharan Africa, resulting in a large sample size of 573 HIV-infected 
children with TB of whom 461 also initiated ART. Second, we used the most appropriate 
methods to measure the effect of delaying ART on mortality in an observational study, 
by controlling for a bias due to confounding by indication and lead time using the IPTW 
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method of marginal structure model. Third, by considering different cut-offs for the 
definition of delay, we were able to elicit a “dose-response” relationship, with a  
tendency of increasing negative effect on both mortality and viral response to ART with 
increasing length of delay. Fourth all children in our cohort came from a single clinic. 
This is important as initiation of TB treatment and assessment of ART involves some 
subjectivity; having the same set of clinicians making those decisions, limits the 
variability.      
Our study also suffered from some limitations. First, this is a retrospective analysis of 
data from an observational clinical cohort. As a consequence, viral load results at TB 
treatment initiation were missing for 15% of children included in the analysis, and 13% 
were lost to follow up. The loss to follow-up was not associated with timing to ART or 
the baseline covariates, and more than half of loss to follow-up occurs prior to ART 
initiation which we accounted for by the censoring weights. Because of the high 
workload, reasons for initiation or delay of ART were not noted. Second, children 
receiving rifampin were treated with efavirenz (if older than 3 years) or ritonavir-boosted 
lopinavir (if 3 years or younger) to achieve optimal virological outcomes [101] [102, 103]. 
These regimens are often not available in most resource poor countries, limiting the 
generalizability of our results to other parts of sub-Saharan Africa. Third, we did not 
have adherence data to adjust for possible differential rates of adherence among 
children initiated on ART earlier and those in whom ART was delayed. In our cohort, 
children with more advanced HIV disease progression at TB initiation were more likely 
to be initiated on ART earlier than those in better clinical status. Compared to 
asymptomatic children,  children in more advanced stage of HIV disease at ART 
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initiation are likely to be more adherent to treatment.[104]. Fourth, due to the small 
number of children not severely immunosuppressed at baseline and particularly the 
limited number of events among them, it was not possible to fully assess effect of 
delaying ART on mortality or viral suppression among those children, it is possible that 
the effect of delaying ART on mortality differs by the level of immunosuppression.   
In conclusion, these results indicate that delaying ART initiation in children with TB for 
more than 60 days may be detrimental for survival and viral response to ART.  These 
results need to be confirmed by a randomized controlled trial of when to start ART in 
children with TB, as results from ongoing adult trials [105] may not be generalizable to 
children.    
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Table VI-1. Characteristics of 573 HIV/TB children 15 years or younger who received care at Harriet Shezi Children Clinic 
in Soweto, South Africa between April 2004 and March 2008 
 
Initiation of ART 
 
Timing of ART initiation  
P-value* Baseline characteristics Overall No Yes P-value* < 1 month >= 1 month 
CD4 cell count: median (IQR) 
392                 
(165 to 773) 
745                
(436 to 1211) 
327 
(137 to 701) <0.01 
273                         
(98 to 604) 
533 
(238 to 868) 
 
<0.01 
CD4 cell percentage: Median (IQR) 
11.90 
(6.60 to 18.30) 
19.55                
(12.10 to 25.90) 
10.10 
(6.00 to 16.50) <0.01 
8.02                
(4.62 to 13.60) 
15.00 
(9.82 to 21.20) 
 
 
<0.01 
Severity of immunosuppression 
 
Mild/not significant/advanced: n(%) 125 (24.80) 45 (53.57) 80 (19.05) 25 (9.62) 74 (38.74)  
Severe†: n(%) 379 (75.20) 39 (46.43) 340 (80.95) <0.01 235 (90.38) 117 (61.26) <0.01 
Log viral load: median (IQR) 
5.20                
(4.54 to 5.88) 
4.91                 
(4.32 to 5.85) 
5.26 
(4.62 to 5.88) 0.02 
5.28                
(4.64 to 5.98) 
5.20                      
(4.52 to 5.80) 
 
0.24 
> 5: n(%) 284 (58.56) 33 (44.59) 251 (61.07) 154 (60.87) 108 (57.75)  
0-5: n(%) 201 (41.44) 41 (55.41) 160 (38.93) 0.01 99 (39.13) 79 (42.25) 0.53 
Weight-for-age z score: Median (IQR) 
-2.28                      
(-3.58 to -1.26) 
-1.63                      
(-3.09 to -0.84) 
-2.38                     
(-3.81 to -1.36) <0.01 
-2.71                      
(-4.11 to -1.60) 
-1.92 
(-2.92 to -0.83) 
 
<0.01 
>=-2SD: n(%) 241 (42.73) 63 (56.25) 178 (39.29) 96 (34.29) 106 (51.46)  
-2 to -3SD: n(%) 127 (22.52) 19 (16.96) 108 (23.84) 62 (22.14) 53 (25.73)  
< -3SD: n(%) 196 (34.75) 30 (26.79) 167 (36.87) <0.01 122 (43.57) 47 (22.82) <0.01 
age at TB treatment initiation: 
median (IQE) years 
3.47              
(1.36 to 6.78) 
2.48                       
(1.26 to 5.54) 
3.65   
(1.37 to 7.04) 0.20 
3.50              
(1.35 to 7.07) 
3.53 
(1.36 to 6.65) 
 
0.45 
0.0 – 1.4: n(%) 158 (27.57) 36 (32.14) 122 (26.46) 78 (27.08) 54 (26.21)  
1.5 – 2.9: n(%) 107 (18.67) 26 (23.21) 81 (17.57) 52 (18.06) 37 (17.96)  
3.0 – 4.9: n(%) 96 (16.75) 17 (15.18) 79 (17.14) 44 (15.28) 41 (19.90)  
5.0 – 15.0: n(%) 212 (37.00) 33 (29.46) 179 (38.83) 0.31 114 (39.58) 74 (35.92) 0.12 
Time from TB to ART initiation: 
median (IQR) days 17 (0 to 49) -  17 (0 to 49) 4 (0 to 14) 59 (42 to 130) 
 
<0.01 
Survival time after TB treatment 
initiation: median (IQR) months 
9.64 
(1.93 to 23.05) 
0.00 
 (0.00 to 2.02) 
14.23 
(5.08 to 26.07) <0.01 
13.97 
(2.89 to 26.39) 
12.66 
(5.74 to 24.20) 
 
 
0.33 
IQR = Interquartile range, SD = Standard Deviation, †CD4 percentage below 25% for children younger than 1, or below 20% for children 1 to 2 years, or below 
15% for children 3 to 15 years. *From Wilcoxon Rank sum test for continuous variables and Pearson Chi Square test for categorical variables
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Table VI-2. Characteristics associated with survival and virologic response of 573 
HIV/TB co-infected ART-naïve children seen at Harriet Schezi children’s clinic, Soweto, 
South Africa (April 2004, March 2008) 
  Mortality   Virological suppression* 
  Total 
eligible  
Number 
of events 
n (%) 
Hazard Ratio 
(95%CI) 
 Total 
eligible 
Number 
of events  
n (%) 
Hazard Ratio 
(95% CI) Baseline characteristics     
Severity of 
immunosuppression         
Mild/not significant/advanced  125 4 (3.20) 1  63 57 (90.48) 1 
 Severe† 
 379 33 (8.71) 2.38 (0.85, 6.68)  250 226 (90.40) 0.89 (0.68, 1.16) 
Viral load (log copies/ml)          
> 5  284 28 (9.86) 1  186 165 (88.71) 1 
0-5  201 8 (3.98) 0.42 (0.19, 0.93)  118 112 (94.92) 1.11 (0.87, 1.42) 
Weight-for-age z score         
>=-2SD  241 5 (2.07) 1  133 125 (93.98) 1 
-2 to -3SD  127 7 (5.51) 2.50 (0.74, 8.36)  75 68 (90.67) 0.70 (0.52, 0.93) 
< -3SD  196 24 (12.24) 6.22 (2.21, 17.54)  112 95 (84.82) 0.79 (0.58, 1.06) 
age at TB treatment initiation: 
years         
0.0 – 1.4  158 21 (13.29) 1  78 62 (79.49) 1 
1.5 – 2.9  107 5 (4.67) 0.32 (0.12, 0.88)  61  56 (91.80) 1.12 (0.76, 1.65) 
3.0 – 4.9  96 4 (4.17) 0.28 (0.09, 0.83)  58 54 (93.10) 1.42 (0.93, 2.16) 
5.0 – 15.0   212 7 (3.30) 0.22 (0.09, 0.51)   127 119 (93.70) 1.41 (1.00, 1.98) 
CI = Confidence Interval: estimated using robust variance, SD = Standard Deviation, *first viral load 
measure below 400 HIV RNA copies/ml. †CD4 percentage below 25% for children younger than 1, or 
below 20% for children 1 to 2 years, or below 15% for children 3 to 15 years. All estimates were obtained 
using the weighted Cox proportional hazard. 
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Table VI-3. Effect of Delaying ART initiation on survival and virologic response among a 
cohort of 483 HIV/TB co-infected ART-naïve children seen at Harriet Schezi children’s 
clinic, Soweto, South Africa (April 2004, March 2008) 
  
Total 
eligible‡†  
Number of 
events‡†   
n (%) 
Hazard Ratio (95%CI) 
Model & Cut-off used for 
exposure   Crude 
Adjusted for 
baseline 
characteristics‡ Weighted** 
Time from TB to ART initiation       
  Mortality† 
  
Overall 
<=15 days  226 22 (9.73) 1 1 1 
> 15 days  275 13 (4.73) 0.44 (0.22, 0.88) 0.73 (0.34, 1.55) 0.90 (0.30, 2.75) 
 
      
<= 30 days  288 25 (8.68) 1 1 1 
> 30 days  206 9 (4.37) 0.46 (0.22, 0.98) 0.72 (0.32, 1.61) 1.05 (0.29, 3.75) 
       
<= 60 days  378 26 (6.88) 1 1  
> 60 days  111 8 (7.21) 0.96 (0.44, 2.12) 1.76 (0.71, 4.40) 2.18 (0.64, 7.48) 
  
Restricted to severely immunosuppressed children at baseline 
<=15 days  184 21 (11.41) 1 1 1 
> 15 days  170 11 (6.47) 0.53 (0.26, 1.09) 0.71 (0.32, 1.59) 1.14 (0.65, 2.01) 
       
<= 30 days  235 24 (10.21) 1 1 1 
> 30 days  117 7 (5.98) 0.56 (0.24, 1.28) 0.68 (0.27, 1.71) 1.36 (0.77, 2.41) 
       
<= 60 days  298 24 (8.05) 1 1  
> 60 days  54 7 (12.96) 1.61 (0.71, 3.67) 2.04 (0.77, 5.44) 3.40 (1.92, 6.02) 
 
 
Virological suppression* 
 
 
Overall 
<=15 days  152 136 (89.47) 1 1  
> 15 days  172 155 (90.12) 1.07 (0.86, 1.35) 0.98 (0.76, 1.26) - 
 
   
   
<= 30 days  197 179 (90.86) 1 1  
> 30 days  127 112 (88.19) 1.03 (0.81, 1.30) 0.95 (0.73, 1.23) - 
       
<= 60 days  265 238 (89.81) 1 1  
> 60 days  59 53 (89.83) 0.96 (0.72, 1.27) 0.84 (0.61, 1.15) - 
  
Restricted to severely immunosuppressed children at baseline 
<=15 days  133 120 (90.23) 1 1  
> 15 days  117 106 (90.60) 1.06 (0.82, 1.37) 0.96 (0.73, 1.26) - 
       
<= 30 days  173 158 (91.33) 1   
> 30 days  77 68 (88.31) 0.96 (0.72, 1.28) 0.91 (0.67, 1.24) - 
       
<= 60 days  222 201 (90.54) 1   
> 60 days  28 25 (89.29) 0.84 (0.57, 1.23) 0.77 (0.50, 1.18) - 
CI = Confidence Interval: estimated using robust variance, *First viral load measure below 400 HIV RNA copies/ml. 
**Weighted with the inverse probability-of-ART-initiation that accounts for time-varying confounding by indication. 
‡Unweighted model that includes severity of immunosuppression (CD4 percentage below 25% for children younger 
than 1, or below 20% for children 1 to 2 years, or below 15% for children 3 to 15 years), viral load, weight-for-age Z 
score, and age at TB treatment initiation as covariates. ‡†For each cut-off of timing to ART, children who are yet to be 
initiated on ART and whose follow-up time is less than the cut-off were excluded.   
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VII. CONCLUSIONS 
A. Overall findings  
Sub-Saharan Africa is home to 9 out of every 10 children living worldwide with HIV. In 
many countries in the region, the sustained declines of child mortality observed since 
the independence have been halted or reversed. In South Africa for example, where 
more than 5% of children 5 years or younger are HIV-infected [106],  HIV accounts for 
57% of all deaths among children under 5 years of age [6]. TB is a major cause of death 
among HIV-infected children in the region. Prevalence of HIV as high as 60% had been 
reported in some of the pediatric TB clinics [8]. Although ART has revolutionized the 
treatment of HIV worldwide and despite the ambitious goal of universal access to ART 
by 2010 [2, 107], access to ART in sub-Saharan Africa in general lags behind that of the 
rest of world and access for children substantially lags behind that of adults and tends to 
be clustered in urban areas [2, 38].  
The major barrier for expanding ART into some of the poorest settings is the lack of 
health care infrastructures including trained health personnel [84]. For example, while 
frequent measurements of viral load and CD4 is the standard for monitoring ART in 
developed countries, the required technologies are not available or sustainable in those 
settings with no electricity and running water. WHO recommends that in settings, 
somatic growth (change in weight and height) be used. However, contrary to viral load 
that has a clear cut-point (below detection limit) clear cut-points for discriminating 
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children that are failing ART from those who are responding are yet to be defined for 
post-ART gains in weight, height, and CD4 count.  
The first aim of this study was to construct reference charts for gains in weight, height, 
absolute CD4 count, and CD4% in the first 6 months of ART, and to assess the value of 
the 3rd, 10th, 25th, 33rd, and 50th percentiles as predictors of subsequent death, 
virological suppression, or treatment failure. We found that children with weight gain 
below the 33rd percentile at 6 months of ART had a four fold hazard of death, 1.6 fold 
hazard of treatment failure and were less likely (adjusted HR 0.8) to achieve viral 
suppression compared to children with weight gains above the 33rd percentile. Similar 
strengths of associations were observed for CD4 cell gain (both absolute count and 
CD4%), but no association was observed between height gain and treatment outcomes. 
These findings suggest that if the usual -2SD (or 3rd percentile) was to be used as cut-
off for identifying children who are failing to gain appropriate weight or CD4 and 
therefore are failing ART, a substantial number of children at higher risk of death or 
treatment failure will be missed. Our results also show that children in our cohort gain 
substantially more weight than non-HIV infected North American children of the Fels 
Institute, indicating that reference distributions of weight gain from normal children are 
inappropriate for HIV-infected children on ART. In fact, it has been shown that weight 
and height velocity of children in the Soweto area might differ from that of children in the 
Fels Cohort [93]. Moreover, one should have expected that the grow velocity in children 
initiated on ART be higher than that of normal children. Following ART initiation there is 
a “catch-up” period of about 12 months during which the weight, height, and CD4 count 
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values of those immuno-suppressed children who were failing to thrive get back close to 
normal values albeit not completely [37].  
Another major challenge for the roll out of pediatric ART in sub-Saharan Africa is the 
high burden of TB/HIV co-infection. Because of the substantial drug interactions and 
common side-effects between anti-TB and ART it is generally recommended to delay 
ART in HIV/TB co-infected children for at least 2-8 weeks. However, the optimal timing 
of ART in those patients is not known. In the aim # 2 of this study, we sought to 
determine the effect of delaying ART for at least 15, 30, or 60 days in HIV/TB co-
infected children on virological suppression and survival. We found that delaying ART 
for less than 30 days after TB treatment initiation had no effect on survival or virological 
response. However, delays for 60 days or longer, though not statistically significant 
tended to increase the hazard of death and decrease that of achieving virologic 
suppression, suggesting that the current recommendation to delay ART in TB infected 
children should be revaluated.  
A. Strengths 
In addition to strengths discussed in chapters V and VI additional, other strengths of this 
study include:   
1) The innovative statistical and epidemiological methods. 
For aim one, we used the GAMLSS and BCPE distribution to construct the reference 
distribution of age-specific six-month gains in weight, height, CD4, and CD4%. 
GAMLSS is a semi-parametric method and because of the smoothed curves they 
produced, semi-parametric methods are the methods of choice for the construction of 
the growth curves are [65, 86]. Moreover, previous studies that used semi-parametric 
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methods to construct growth curves assumed a skewed normal distribution for the 
outcome variable [55, 66] and used the Box Cox power transformation to correct for 
potential skewness [67]. However, though kurtosis is not a major contribution to non-
normality, presence of important kurtosis that is not accounted for has the potential to 
bias the estimated centiles curves. In our analyses, important kurtosis was present for 
the distribution of six-month weight and height gains for male, and CD4 gain. BPCE and 
GAMLSS are also the methods adopted by the WHO for the construction of growth 
reference [69].    
For study aim #2, the major methodological challenges were to account for the time-
varying confounding by indication introduced by the fact that sicker children who were at 
greater risk for death were more likely to be initiated on ART earlier while treatment was 
delayed for healthier ones. There was also a lead time that resulted from the fact that 
children in whom ART was delayed could die before ART initiation or before they could 
be classified for exposure. Special techniques were required to adjust for those two 
potential sources of bias.  The IPTW method of marginal structural modelling is a valid 
method to account for those sources of bias assuming that the models for estimating 
the stabilized weights were not misspecified and that there were no unmeasured 
confounders [78]. With the IPTW we were able to account for substantial amount of bias 
in our estimate as evidenced by the difference between the results from multivariate 
Cox models and marginal structural models.  
2) Careful definition of exposure for each of the aim and multiple outcomes 
Whether for aim 1 or 2, we considered multiple cut-offs for the definition of exposures. 
For aim 1, previous studies that examined the association of growth velocity with the 
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prognosis of HIV [55] or response to ART [50], treated the normalized six-month weight 
and height gains as continuous and estimated the effect associated with 1SD change in 
six-month somatic growth. No specific cut-point was explored [55]. In the latter study 
after converting the weight and height  measurements in Z score using the CDC 
database, they used +1SD (~90th percentile) as cut [50]. The WHO recommendation 
refers to children who are failing to thrive, which correspond to children falling below -
2SD or ~3rd percentile. By considering multiple cut-points, we were able to show that -
2SD is a too conservative cut-point because even children whose six-month weight 
gains were above the 33rd percentile were still at higher risk of treatment failure and 
death and needed closer follow-up.   
For aim 1 as well as aim 2, with multiple cut-offs for the exposure, we were able to elicit 
a sort of “dose response” response relationship between exposure and outcomes that 
served as a proxy for the consistency of our results. In addition to multiple cut-points for 
the exposure, our consistent results across multiple outcomes could also be viewed as 
another indirect element of the internal validity of our study. 
B. Limitations 
Beyond the limitations discussed in chapter V and VI, for aim 1, we only examined the 
six-month gains in weight, height, CD4 and CD4%. Six months is the interval that has 
been used in the previous two similar studies [50, 55] and corresponds to the interval 
recommended for repeating viral load and CD4 in the clinic [57]. However, for some 
children, there might be a need for monitoring at closer intervals. Moreover, monitoring 
of ART does not stop after the first six months. Reference distributions for shorter 
intervals and beyond the first six months of ART are needed. Moreover, as we touched 
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on in the manuscript of paper #1, we used information from children treated in one 
single clinic in a poor urban neighborhood in South Africa. It is hard to speculate how 
results from this single cohort are generalizable or not to all HIV-infected children in 
South Africa or to the rest of the continent and beyond. However, results from the WHO 
multicenter growth study suggest that, when their health and nutrition needs are met, 
non HIV-infected children from diverse region of the world experience similar patterns of 
growth [69].  
For aim 2, almost half of eligible children were excluded from the analysis because they 
were already on TB treatment at the first visit in the clinic and we were unable to 
determine how long they had been on it. Our study thus had a small sample size and 
our estimates had wide confidence intervals. Finally, the main assumption for 
interpreting our estimates as causal is that there were no unmeasured confounders. 
This is a strong assumption for an observational clinical cohort. Some indicators of ART 
such as hospitalization or social factors were not available in the dataset, and particular 
reasons for why a child was initiated on ART or delayed at a given visit were not 
recorded. Moreover for viral suppression, data on adherence was also not available. 
However, we do not believe that the residual bias alone, could explain our results.  
C. Future directions 
For public health: Our reference curves provide practitioners in settings where they 
have to use weight or CD4 as sole tools for monitoring the response to ART in HIV-
infected children, effective and simple screening tools for discriminating those who are 
responding from those who are not responding well to ART. However, reference 
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distributions for shorter intervals and for longer follow-up period need to be constructed 
and the tools have to be introduced to clinicians in the field.  
Despite the lack of statistical significance for the results of aim 2, they provide some 
evidence to clinicians and policy makers to reconsider the actual recommendation of 
delaying ART initiation in HIV/TB co-infected children. If the need to separate side 
effects of anti-TB from that of ART is deemed too important to justify the delay, it should 
not be more than 2 weeks.  
For future research: For growth curves, in addition to obtaining more samples that will 
enable generalizing more broadly, future studies should consider shorter intervals and 
should go beyond the first 6 months of ART.  
For timing of ART in HIV/TB co-infected children, in the absence of a randomized 
control trial, future studies should at least be prospective and appropriately powered.  
Methodological considerations: GAMLSS is a new analytic technique and despite the 
flexibility it provides relative to the generalized linear model, it is yet to be introduced in 
analysis of epidemiological data. Potential areas of application might include for 
example overdispersion with count poisson data, parametric modeling of survival time, 
and other continuous or ordinal variable where simple logarithmic transformations fail to 
normalize it. 
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VIII. APPENDICES 
A. Q-statistics and its interpretation 
The main assumption of the Box-cox power exponential regression model is that after 
the appropriate transformation, the distribution of outcome is normally distributed 
independently of age and residuals should have a normal distribution and this can be 
evaluated using the residuals plots. However, the residual plots are not power to detect 
age related departure from the model (i.e. a poor fit of the model at given age point). To 
this end, Q-test have recently been proposed [72]. For the test, age is categorized in 
groups of approximate equal size and the Q-test statistics which are sensitive to age 
dependency are computed for the first four moments, z1, z2, z3, z4. Values larger than 
2 indicate misfit of respectively the mean, variance, skewness or kurtosis. 
B. Worm Plot and interpretation 
The worm plot is a collection of detrended Q-Q plots, each of which applies to one of 
successive age groups. The data plot in each plot form a worm-like string. The shape of 
the worm indicate how the data differ from the assumed underlying distribution [73]. A 
flat worm indicates a good fit. The table below summarizes the interpretation of different 
patterns of the worm plot.
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Table VIII-1. Interpretation of various patterns in the worm plot.  
Shape Moment If the Then the 
Intercept Mean  Worm passes above the origin 
Worm passes below the origin 
Fitted mean is too small 
Fitted mean is too large 
Slope Variance Worm has a positive slope, 
Worm has a negative slope, 
Fitted variance is too small 
Fitted variance is too large 
Parabola Skewness Worm has a U-shape, 
Worm has an inverted U-shape 
Fitted distribution is too skew to the left. 
Fitted distribution is too skew to the right. 
S-curve Kurtosis Worm has an S-shape on the left bent down, 
Worm has an S-shape on the left bent up, 
Tails of the fitted distribution are too light. 
Tails of the fitted distribution are too heavy 
Source: [73] 
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C. GAMLSS Models diagnostics  
Overall, the fit of our models was relatively good. But for all our models the fit at 
extreme lower value for age was quite as good, particularly for the model for weight in 
female and absolute CD4 count. Transformation of age did improve the fit in those 
regions. But given that we are not focusing on extreme centile which would be much 
affected but those violations, and for the simplicity and interpretability of the constructed 
curve we proceeded with our models as presented.  
Note: when df(υ) =0 (υ=1) and df(τ)=0 (τ =2), the BCPE distribution simplifies to the 
Box-Cox Cole and Green LMS distribution.  
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Weight gain male 
 
Model: BCPE (age, df(µ) = 4, df(σ) = 0.5,  df(υ) =0, df(τ)=1) 
 
Table VIII-1. Q-statistics for the goodness-of-fit of finial model for weight gain in males 
 
Z1 Z2 Z3 Z4 AgostinoK2 N 
0.68035 to 1.56468 0.753343 -0.59917 -1.14248 0.463149 1.519774 63 
1.56468 to 2.42436 0.640133 0.1941 0.044676 -1.55722 2.426925 62 
2.42436 to 3.18822 -0.67988 0.424044 1.201748 0.266181 1.515051 63 
3.18822 to 4.08076 -0.65597 0.371518 -0.30841 0.14874 0.117237 63 
4.08076 to 5.19507 0.237683 -0.91227 0.486766 -0.17307 0.266894 63 
5.19507 to 6.12320 0.108389 -0.75613 -1.05729 0.668627 1.564917 62 
6.12320 to 7.26488 0.64693 1.223694 -0.00754 0.655597 0.429864 63 
7.26488 to 8.55715 -0.29321 1.13767 -0.29022 -0.35274 0.208653 63 
8.55715 to 10.2600 0.234524 -0.54883 -0.03799 1.252063 1.569105 62 
10.2600 to 14.2874 0.023547 0.159488 0.435311 -0.75528 0.759951 63 
TOTAL Q stats 2.498107 5.236869 4.476593 5.901777 10.37837 627 
df for Q stats 3.999227 8.249898 7.97512 7.000358 14.97548 0 
p-val for Q stats 0.644857 0.75417 0.809858 0.551305 0.793911 0 
 
Figure VIII-1. Worm plots for the final model for weight gain among males 
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Weight gain female 
Model: BCPE (age, df(µ) = 5.3, df(σ) = 0, df(υ) =0, df(τ)=0) 
 
Table VIII-2. Q-statistics for the goodness-of-fit of finial model for weight gain in females 
 
Z1 Z2 Z3 Z4 AgostinoK2 N 
0.75154 to 1.28542 2.007267 -1.27786 0.328482 -1.10459 1.328023 60 
1.28542 to 2.04928 -2.05858 1.745161 -0.35878 1.724085 3.10119 60 
2.04928 to 2.94455 -0.40893 -1.70453 -1.62114 -0.58662 2.972218 61 
2.94455 to 3.93292 0.450993 0.300249 2.319167 1.566385 7.8321 61 
3.93292 to 4.99520 0.087439 -0.28438 0.913401 2.651014 7.862178 59 
4.99520 to 6.12046 -0.36081 1.637159 0.528791 -0.88927 1.070419 60 
6.12046 to 7.44558 0.399437 -0.91208 1.095213 1.757966 4.289935 60 
7.44558 to 8.81451 0.389042 -0.34063 1.756777 -0.35594 3.212959 61 
8.81451 to 10.2765 -0.3326 -0.43225 0.408673 0.665923 0.610467 60 
10.2765 to 15.1088 -0.03571 0.336292 -2.59883 0.162253 6.780231 60 
TOTAL Q stats 9.198117 11.68308 20.56385 18.49587 39.05972 602 
df for Q stats 3.868961 8.492491 9 10 19 0 
p-val for Q stats 0.051616 0.197033 0.014734 0.047153 0.004339 0 
 
Figure VIII-2. Worm plots for the final model for weight gain among males 
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Height gain male 
Model: BCPE (age, df(µ) =9.1 , df(σ) =0 , df(υ) =0, df(τ)=2) 
 
Table VIII-3. Q-statistics for the goodness-of-fit of finial model for Height gain in males 
 
Z1 Z2 Z3 Z4 AgostinoK2 N 
0.68035 to 1.38672 1.27526 0.381458 -0.0689 -0.63693 0.410428 44 
1.38672 to 2.01368 -1.56072 0.281042 -0.2351 -0.47343 0.279407 44 
2.01368 to 2.61054 -0.47297 0.875998 -0.24158 -0.15528 0.082471 43 
2.61054 to 3.11704 0.415657 0.342519 0.435325 0.244075 0.24908 44 
3.11704 to 3.67282 -0.02562 -2.4071 1.610587 1.467083 4.746324 44 
3.67282 to 4.34633 0.33205 0.207718 0.937359 -0.44964 1.080819 44 
4.34633 to 5.18138 0.528128 -0.39264 -2.12795 1.220003 6.016582 43 
5.18138 to 5.79466 -0.5351 -0.54854 0.142027 1.156836 1.358442 44 
5.79466 to 6.54757 -0.33341 -0.31166 1.763032 1.306524 4.815286 44 
6.54757 to 7.42094 -0.26791 0.939945 0.900098 -1.15452 2.143097 44 
7.42094 to 8.22313 0.257151 -1.90244 -0.79888 0.178359 0.670015 44 
8.22313 to 9.41409 -0.82758 0.392116 -1.48084 -0.13978 2.21242 43 
9.41409 to 11.0184 -1.33601 0.665045 1.544616 1.466037 4.535104 44 
11.0184 to 14.7091 0.08955 0.299359 -0.1474 -0.64602 0.439071 44 
TOTAL Q stats 7.861671 12.68709 17.48598 11.55257 29.03855 613 
df for Q stats 2.89827 12.49148 11.98122 10.00051 21.98173 0 
p-val for Q stats 0.045174 0.431477 0.131427 0.316157 0.143161 0 
 
Figure VIII-3. Worm plots for the final model for height gain among males 
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Height gain female 
Model: BCPE (age, df(µ) =7, df(σ) =0, df(υ) =0, df(τ)=0) 
 
Table VIII-4. Q-statistics for the goodness-of-fit of finial model for weight gain in females 
 
Z1 Z2 Z3 Z4 AgostinoK2 N 
0.75154 to 1.24982 2.524756 -0.92259 0.403968 -0.59655 0.519058 54 
1.24982 to 1.91512 -2.21731 0.484323 2.321226 1.946641 9.177505 54 
1.91512 to 2.72005 -1.00522 1.573861 -0.21604 -0.01901 0.047035 54 
2.72005 to 3.64544 0.316918 -1.21314 0.722675 0.530918 0.804133 54 
3.64544 to 4.61464 -0.05207 -1.72777 -1.54618 -0.40157 2.551919 54 
4.61464 to 5.64681 0.603876 -0.60191 -1.1207 0.124588 1.271497 54 
5.64681 to 6.72826 -0.32348 0.779021 -0.84604 -0.3555 0.842171 54 
6.72826 to 7.81245 -0.16848 0.447394 2.255154 2.445696 11.06715 54 
7.81245 to 9.01437 -0.08185 -0.55527 -1.25779 0.973282 2.529316 54 
9.01437 to 10.4654 0.462762 -0.70317 0.698815 -1.28756 2.146155 54 
10.4654 to 14.3805 -0.05482 1.010861 -0.05086 -0.3248 0.108083 54 
TOTAL Q stats 13.12603 11.01362 17.64133 13.42269 31.06402 594 
df for Q stats 2.201042 9.493401 8.985375 8.985916 17.97129 0 
p-val for Q stats 0.001818 0.314328 0.039301 0.143669 0.028015 0 
 
Figure VIII-4 Worm plots for the final model for height gain among females 
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CD4 percentage gain 
Model : BCPE (age, df(µ) = 0, df(σ) = 5, df(υ) =0, df(τ)=0) 
 
Table VIII-5. Q-statistics for the goodness-of-fit of finial model for CD4% gain 
 
Z1 Z2 Z3 Z4 AgostinoK2 N 
0.65571 to 1.34565 -0.20463 1.309294 0.191018 -0.27737 0.113421 106 
1.34565 to 2.06297 -0.85258 -0.1745 -0.82565 0.278797 0.759429 106 
2.06297 to 2.85694 -0.21539 -2.1985 -0.22455 -2.57753 6.694096 106 
2.85694 to 3.80424 0.247904 -0.48251 1.098682 0.642409 1.619792 106 
3.80424 to 5.02532 2.124456 1.284236 -0.08319 -0.89854 0.814293 106 
5.02532 to 5.99999 -0.15714 0.31015 -0.78325 1.549324 3.013884 105 
5.99999 to 7.17727 0.385877 -0.1298 -1.24144 1.201899 2.985743 106 
7.17727 to 8.43668 -0.65773 -0.97501 0.393026 -2.41913 6.006639 106 
8.43668 to 10.2600 -0.03182 0.473693 0.22752 0.896653 0.855752 106 
10.2600 to 14.7994 0.510112 0.186189 0.73189 0.127458 0.551908 106 
TOTAL Q stats 6.257357 9.7829 4.879195 18.53576 23.41496 1059 
df for Q stats 7.914749 6.999646 9 9 18 0 
p-val for Q stats 0.609623 0.201188 0.844709 0.029443 0.175144 0 
 
Figure VIII-5. Worm plots from the model for CD4% gain  
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Absolute CD4 count  
Model: BCPE (age, df(µ) = 3, df(σ) = 0, df(υ) =0, df(τ)=1) 
 
TableVIII-6. Q-statistics for the goodness-of-fit of finial model for absolute CD4 gain 
 
Z1 Z2 Z3 Z4 AgostinoK2 N 
0.65571 to 1.36755 1.947251 0.71608 -0.5052 -1.70078 3.147884 106 
1.36755 to 2.09856 -0.89405 0.253593 -0.26231 1.218888 1.554497 105 
2.09856 to 2.90622 -1.07904 -0.46138 0.618735 0.0352 0.384072 105 
2.90622 to 3.86995 -0.3166 -1.06151 0.26402 0.722429 0.59161 106 
3.86995 to 5.12936 0.663851 0.791278 -1.6178 -0.43472 2.806248 106 
5.12936 to 6.12320 0.895421 -1.83715 2.599934 1.326597 8.519515 105 
6.12320 to 7.26488 -0.38414 0.037088 0.344691 -0.09243 0.127355 105 
7.26488 to 8.55715 1.028 0.193066 -0.83233 0.291286 0.777627 107 
8.55715 to 10.2874 0.064079 1.2119 0.205509 1.722284 3.008495 105 
10.2874 to 14.7994 0.956308 -0.39573 0.567051 -0.57468 0.6518 105 
TOTAL Q stats 9.221123 7.581947 11.32887 10.24023 21.5691 1055 
df for Q stats 4.99944 8.46427 7.953775 6.999704 14.95348 0 
p-val for Q stats 0.100533 0.523177 0.180768 0.175344 0.117995 0 
 
Figure VIII-6. Worm plots from the model for absolute CD4 count gain 
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